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ABSTRACT: Plasmodium parasites, the causative agents of malaria,
have developed resistance to most of our current antimalarial
therapies, including artemisinin combination therapies which are
widely described as our last line of defense. Antimalarial agents with a
novel mode of action are urgently required. Two Plasmodium
falciparum aminopeptidases, PfA-M1 and PfA-M17, play crucial roles
in the erythrocytic stage of infection and have been validated as
potential antimalarial targets. Using compound-bound crystal
structures of both enzymes, we have used a structure-guided
approach to develop a novel series of inhibitors capable of potent
inhibition of both PfA-M1 and PfA-M17 activity and parasite growth
in culture. Herein we describe the design, synthesis, and evaluation of
a series of hydroxamic acid-based inhibitors and demonstrate the
compounds to be exciting new leads for the development of novel
antimalarial therapeutics.
■ INTRODUCTION
Malaria, caused by parasites of the genus Plasmodium (of which
Plasmodium falciparum, Pf, is the most lethal), is the world’s
most prevalent parasitic disease. The spread of drug-resistant
parasites has rendered most of the current antimalarial
treatments ineﬀective; consequently, prevention and treatment
of malaria is becoming increasingly diﬃcult. The most recent
WHO World Malaria Report indicated that, in 2012 alone,
there were approximately 627 000 deaths from malaria. There is
an urgent need for next-generation antimalarial agents with
novel modes of action.
During the symptomatic erythrocytic stage of Pf infection,
parasites degrade hemoglobin into free amino acids.1,2 These
free amino acids are essential in a variety of critical processes,
including parasite growth and development,2 protein synthesis,
and maintenance of osmotic pressure within the infected red
blood cell to prevent premature cell lysis.3 The ﬁnal stage of
hemoglobin digestion is mediated by metalloaminopeptidases
(MAPs), which act to degrade small peptide fragments into free
amino acids.4,5 Inhibitors of these enzymes thus represent
attractive leads for the development of novel antimalarial
therapeutic agents. Pf employs two neutral MAPs, PfA-M1 and
PfA-M17. Both enzymes bear zinc-binding motifs that have
essential roles in both substrate and inhibitor binding.6
Inhibition of PfA-M1 and PfA-M17 has been shown to
control both Pf laboratory and Plasmodium chabaudi chabaudi
murine models of malaria,7,8 and while potent inhibitors of
either PfA-M1 or PfA-M17 have been identiﬁed,7−12 diﬀerences
in the compound binding proﬁles of the enzymes mean that
compound elaboration generally favors selectivity for one
enzyme over the other. Previous work within our group
identiﬁed ((4-(1H-pyrazol-1-yl)phenyl)aminomethyl)-
phosphonic acid (1) (Figure 1) as a lead for the development
of a dual inhibitor of both PfA-M1 and PfA-M17.13 X-ray crystal
structures of both enzymes in complex with 1 showed that the
compound sits within the S1 pocket and coordinates the
catalytic zinc ion(s) through the aminophosphonate moiety.13
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Although aminophosphonates are an established zinc-binding
group (ZBG), the phosphonic acid group would exist as a
dianion at physiological pH (pKa = 2.35 and ∼6)14 with
potentially detrimental eﬀects on membrane permeability. To
generate dual PfA-M1/PfA-M17 inhibitors and address
potential permeability issues conferred by the aminophospho-
nate moiety, we sought to employ an alternative ZBG.
Hydroxamic acid-based compounds that are capable of reaching
the site of action within infected red blood cells and inhibiting
PfA-M1 have been described previously.10 Therefore, we
replaced the phosphonic acid moiety of 1 with a hydroxamic
acid to generate compounds that would have a more desirable
permeability15,16 and plasma stability proﬁle.17 The hydroxamic
acid group has been successfully used in inhibitors for several
proteases, the most attractive being tosedostat, which shows
promising eﬃcacy in phase II clinical trials for patients with
myelodysplastic syndrome and/or acute myeloid leukemia.18
Herein, we report the design, synthesis, and inhibitory activity
of novel carboxylic and hydroxamic acid derivatives of 1,
leading to the discovery of compound 7 as a potent dual
inhibitor of PfA-M1/PfA-M17. Utilizing compound 7 as our
new lead, we investigated structure−activity relationships
(SARs) of this scaﬀold further through a series of N-acyl
derivatives in replacement of the N-Boc group. Finally, we
demonstrate parasiticidal activity of our more potent dual
inhibitors.
■ RESULTS AND DISCUSSION
Chemistry. It was envisaged that the desired α-amino-
hydroxamic acid functionality could be accessed from the
corresponding N-Boc-protected amino acid by ﬁrst coupling
with hydroxylamine before N-Boc deprotection to unmask the
ﬁnal compound. Our initial strategy employed 2-amino-2-(4-
bromophenyl)acetic acid as a starting material. N-Boc
protection of the amine and esteriﬁcation of the carboxylic
acid functionality were performed, prior to attempted Ullmann-
type coupling with pyrazole under a variety of conditions,19−21
none of which were successful (data not shown). Suspecting
the presence of the bulky protected amine and carboxylic acid
groups to be responsible for the failed coupling (through either
a steric or a potentially catalyst-chelating mechanism), an
alternative strategy was devised, whereby Ullman-type N-
arylation of pyrazole could be carried out with a simple
coupling partner, with subsequent installation of the α-amino
acid functionality (Scheme 1).
Literature precedent for the synthesis of 1-(4-(1H-pyrazol-1-
yl)phenyl)ethan-1-one (3) in good to excellent yield is
widespread.22−33 In our hands, N-arylation of pyrazole with
4′-iodoacetophenone (2) to give 3 was achieved in near-
quantitative yield using copper(I)-catalyzed, ligand-free Ull-
man-type coupling.21 Subsequent oxidation of 3 to the
corresponding α-keto acid 4 was achieved with ease, using
SeO2/pyridine as the oxidation system.
34 Installation of the
racemic amino acid system was carried out through initial
reductive amination of the ketone moiety of 4 with N,N-
dibenzylamine and Na(OAc)3BH under standard conditions.
35
The intermediate N,N-dibenzyl-protected amino acid then
underwent complete debenzylation in the presence of 10% Pd/
C in acidiﬁed methanol under a hydrogen atmosphere. Finally,
N-Boc protection of the HCl salt of the intermediate amino
acid was carried out using Boc2O under mildly basic conditions.
After puriﬁcation, 2-(4-(1H-pyrazol-1-yl)phenyl)-2-((tert-
butoxycarbonyl)amino)acetic acid (5) was obtained in 56%
yield over three steps.
The hydroxamic acid ZBG has commonly been derived from
the corresponding carboxylic acid precursor. In many cases the
carboxylic acid group has also been found to possess the ability
to bind zinc ions, albeit generally more weakly than the
corresponding hydroxamic acid.15,16 With this in mind, we
chose to evaluate the inhibitory activity of both the carboxylic
Figure 1. ((4-(1H-Pyrazol-1-yl)phenyl)aminomethyl)phosphonic acid
(1).13
Scheme 1. Synthesis of Carbonyl Derivatives of ((4-(1H-Pyrazol-1-yl)phenyl)aminomethyl)phosphonic Acid (1)a
aReagents and conditions: (a) pyrazole, Cs2CO3, Cu2O, DMF, 100 °C, 97%; (b) SeO2, anhydrous pyridine, 110 °C, 92%; (c) N,N-dibenzylamine,
Na(OAc)3BH, 1,2-dichloroethane, rt; (d) H2, 10% Pd/C, concd HCl, MeOH, water, rt; (e) NaHCO3(aq), Boc2O, THF, rt, 56% (over three steps);
(f) 4 M HCl/1,4-dioxane, DCM, rt, 25−97%; (g) (i) CDI, THF, rt; (ii) NH2OH·HCl, rt, 69%.
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acid and hydroxamic acid derivatives of 1. N-Boc deprotection
of 5 in the presence of 4 M HCl/dioxane and DCM aﬀorded
the HCl salt of the α-aminocarboxylic acid derivative 6 in near-
quantitative yield. In contrast, the desired hydroxamic acid
derivative was accessed via a two-step procedure. Initial
conversion of N-Boc-protected α-aminocarboxylic acid 5 to
the corresponding N-Boc-protected α-aminohydroxamic acid 7
was achieved in good yield by CDI-mediated activation
followed by condensation with NH2OH·HCl under the
reported conditions.36 Finally, the desired α-aminohydroxamic
acid 8 was obtained in the HCl salt form through N-Boc
deprotection of 7.
Evaluation of the inhibitory activity of 5−8 against PfA-M1
and PfA-M17 revealed N-Boc-protected α-aminohydroxamic
acid 7 to be a potent, submicromolar inhibitor of both enzymes
(Table 1). We were therefore curious to investigate the eﬀect
that other moieties would have at this position. To this end, we
developed a series of N-acyl derivatives, based on 7, comprised
Table 1. Inhibition of PfA-M1 and PfA-M17 by Novel Hydroxamic Acid Derivatives 5−8 and 13a−m
Ki
a (μM) IC50 ± SD
b (nM)
R1 R2 rPfA-M1 rPfA-M17 Pf 3D7
5 Boc OH >500 464
6 H·HCl OH >500 >500
7 Boc NHOH 0.8 0.03 783 ± 86.6
8 H·HCl NHOH 74.5 86
13a CH3(CO) NHOH 113 0.019 619 ± 52.7
13b CH3CH2(CO) NHOH 41.3 0.016 455 ± 60.9
13c (CH3)2CH(CO) NHOH 12.3 0.053 532 ± 13.3
13d tBu(CO) NHOH 0.7 0.028 227 ± 4.24
13e tBuNH(CO) NHOH 15.3 0.038 597 ± 10.2
13f benzoyl NHOH 23 0.154
13g 2-ﬂuorobenzoyl NHOH 1.9 0.008 351 ± 29.8
13h 3-ﬂuorobenzoyl NHOH 4 0.035 429 ± 30.6
13i 4-ﬂuorobenzoyl NHOH 11.2 0.012 703 ± 49.8
13l 3-aminobenzoyl NHOH 5.5 0.014 233 ± 124.8
13m 4-aminobenzoyl NHOH 7.4 0.011 228 ± 23.47
aKi values were calculated using Dixon plots of 1/V versus inhibitor concentration while the substrate concentration was maintained lower than that
of the Km of the enzyme. Dixon plots can be found in Supplementary Figure 1 (Supporting Information).
bIC50 values were calculated against P.
falciparum 3D7. See also Supplementary Figure 6 (Supporting Information).
Scheme 2. Synthesis of Amide and Urea Analogues of tert-Butyl (1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-
oxoethyl)carbamate (7)a
aReagents and conditions: (a) (i) benzylamine, anhydrous 1,2-dichloroethane, rt; (ii) Na(OAc)3BH, rt, 76%; (b) concd H2SO4, MeOH, reﬂux, 89%;
(c) (i) H2 (balloon), 10% Pd/C, concd HCl, MeOH; (ii) satd NaHCO3 workup; (iii) 1 M HCl/Et2O, Et2O, DCM, 87%; (d) (i) TEA, DCM; (ii)
acid chloride or isocyanate, 85−99%; (e) substituted benzoic acid, HCTU, DIPEA, DCM, DMF, rt, 100%; (f) 10% Pd/C, MeOH, rt, 91−97%; (g)
(i) NH2OH·HCl, MeOH, rt; (ii) KOH/MeOH, 35−68%; (h) (i) NH2OH·HCl, MeOH, rt; (ii) KOH/MeOH; (iii) FCC puriﬁcation to isolated
acid; (iv) CDI, dry THF, rt; (v) NH2OH·HCl, 4−8%; (i) (i) dry MeOH, rt; (ii) NH2OH·HCl, 5 M KOH/MeOH, dry MeOH (premixed), 43−
47%.
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of simple linear and branched alkyl groups as well as substituted
aryl moieties. Access to these compounds was achieved from
the previously synthesized compound 4 in ﬁve to six steps
(Scheme 2).
As described above, α-keto acid 4 underwent reductive
amination with benzylamine rather than N,N-dibenzylamine to
improve the rate and reaction outcome (the corresponding
reaction with N,N-dibenzylamine proceeded slowly, and
complete conversion was not achieved). The new conditions
were successful, and the reaction was complete after overnight
stirring, generating the N-benzylamino acid 9 in good yield.
This was subsequently esteriﬁed with MeOH in the presence of
catalytic concentrated H2SO4(aq) to give the corresponding
methyl ester 10. Attempts to obtain 10 through a reversal of the
reaction sequence (i.e., esteriﬁcation followed by reductive
amination) proved unsuccessful. Heating 4 under the
esteriﬁcation conditions described above resulted in both
methyl ester formation and conversion of the ketone to the
corresponding dimethyl ketal. Although selective deprotection
of the ketal was achieved by allowing it to stand in TFA,37
attempted reductive amination of the resulting α-keto ester
produced several side products by LC/MS analysis, including
the ketone 3, the α-keto alcohol (total reduction of the ester),
the α-hydroxy ester (ketone reduction), and the N-
benzylamino acid 9.
N-Debenzylation of 10 was achieved as described under
acidic hydrogenation conditions in excellent yield, aﬀording α-
amino ester 11 as the HCl salt. Compound 11 underwent
acylation with a selection of alkyl and substituted benzoyl
chlorides, benzoic acids, and tert-butyl isocyanate. Where an
acid chloride or tert-butyl isocyanate was used as the
electrophile, it was simply stirred with 11 in the presence of
a slight excess of TEA to give the corresponding amide or urea
in excellent yield, with only aqueous workup required to isolate
the desired product cleanly. Coupling to substituted benzoic
acids was achieved in the presence of HCTU/DIPEA in DMF
at room temperature, once again with only simple aqueous
workup necessary to aﬀord high-purity amide product. The
nitrobenzamides 12j−k were reduced to the corresponding
aminobenzamides over 10% Pd/C in MeOH under a hydrogen
atmosphere in excellent yield.
Evaluation of the literature indicated successful aminolysis of
simple esters on similar scaﬀolds with NH2OH·HCl
directly.38−44 Such a conversion is attractive as it removes the
need to hydrolyze the ester prior to a coupling step. After
conducting successful pilot reactions, we opted to employ the
combination of NH2OH·HCl and methanolic KOH.
43 These
conditions gave mixed results for the conversion of methyl
esters 12a−i and 12l−m to the corresponding hydroxamic
acids. Following the literature procedure, we obtained the
desired compounds in modest yield in the majority of cases,
with the remainder of reactions aﬀording the corresponding
carboxylic acid (through basic hydrolysis) as the major product.
Even in cases where the desired hydroxamic acid was
successfully isolated, generation of the carboxylic acid product
was also noted. Where only the carboxylic product was isolated,
this was converted to the corresponding hydroxamic acid
product using CDI-mediated activation as described earlier in
the synthesis of 7.
Further optimization of the aminolysis conditions allowed
more consistent conversion to the desired hydroxamic acid
product, with a lower proportion of hydrolysis to the carboxylic
acid being observed by LC/MS analysis. These conditions
involved the use of anhydrous MeOH as the reaction solvent
and to make up the methanolic KOH solution. In addition, the
KOH stock solution was stored under a septum under an
atmosphere of nitrogen to exclude exposure to moisture.
Finally, rather than sequential addition of NH2OH·HCl and
methanolic KOH, the two were premixed before addition to the
appropriate ester reagent. This was done with a view to freshly
generate the free NH2OH nucleophile prior to addition, thus
reducing the concentration of circulating hydroxide ions and
reducing the risk of ester hydrolysis.
The Hydroxamic Acid Compound Series Probes the
S1′ Cavity of PfA-M1 and PfA-M17. In synthesizing 8, the
aminohydroxamic acid analogue of aminophosphonic acid 1,
we identiﬁed 7, the N-Boc precursor of 8, as a potent inhibitor
of both PfA-M1 and PfA-M17 (Table 1; Supplementary Figure
1, Supporting Information). The PfA-M1 inhibitory activity of 7
(Ki = 0.8 μM) is approximately 100-fold higher than that of 1
(Ki = 104 μM), while the PfA-M17 activities are comparable
(the Ki of 1 is 0.011 μM, and that of 7 is 0.03 μM), making 7
the most potent dual PfA-M1/M17 inhibitor described to date.
To assess the selectivity of 7 for PfA-M1 and PfA-M17 over
other MAPs, the inhibitory activity against PfM18AAP, another
P. falciparum MAP,45 was determined. The observed Ki for
PfM18AAP, 49.6 μM, showed that 7 is >60-fold and 1600-fold
selective for PfA-M1 and PfA-M17, respectively. To investigate
the structural mechanism behind the improved PfA-M1 and
PfA-M17 potency, we determined the cocrystal structure of
compound 7 bound to PfA-M1 (PfA-M1:7) and PfA-M17 (PfA-
M17:7). Similarly to 1, compound 7 coordinates strongly to the
catalytic zinc ion(s) of both PfA-M1 and PfA-M17 and probes
the hydrophobic S1 pocket with the aromatic regions of the
compound (namely, a 4-(1H-pyrazol-1-yl)phenyl moiety).
However, the N-Boc group, which is not present on 1, was
observed binding within the S1′ cavity. Since the S1′ cavity has
not previously been explored with this series of inhibitors, we
chose to probe the region with a focused library of N-acyl
derivatives, assessing dual PfA-M1/M17 inhibitory activity and
using structural information obtained from a combination of X-
ray crystallography and docking analysis to guide inhibitor
development.
The crystal structures of PfA-M1 and PfA-M17 bound to
selected compounds in the series were determined by either
cocrystallization or soaking experiments. Similarly to previous
ligand-bound PfA-M1 and PfA-M17 crystal structures, the only
structural diﬀerences observed on compound binding occurred
within proximity of the active sites, while the overall protein
folds and domain arrangements were unchanged. In all
structures, PfA-M1 crystallized as a monomer, with one copy
in the asymmetric unit. In accordance with previous
observations, PfA-M17 crystallized as a functional hexamer,
with two copies in the asymmetric unit; each structure of PfA-
M17 therefore contains a total of 12 binding sites. Although
minor diﬀerences in the quality of the ligand electron density
are observed between the sites, the compound binding mode is
largely conserved. Therefore, for clarity, when referring to
structural features, we refer to the chain that showed the
clearest electron density only (PfA-M17:7, chain B; PfA-
M17:13l, chain C; PfA-M17:13m, chain C). The electron
density was such that while racemic mixes of compounds were
used for crystallization, only the S-enantiomer of 7 and the R-
enantiomer of 13d, 13l, and 13m could be modeled for both
enzymes (Supplementary Figure 2, Supporting Information).
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The Geometry of the ZBG Dictates the Ligand
Binding Position. The current series of compounds was
anticipated to improve inhibitory potency by replacing the
phosphonic acid ZBG present on 1, a potent PfA-M1/PfA-M17
inhibitor (Figure 1), with a hydroxamic acid moiety. As has
been observed for all ligand-bound PfA-M1 crystal structures to
date, PfA-M1:7 revealed the zinc ion to be coordinated by
residues of the catalytic triad: His496, His500, and Glu519. In
addition, both oxygen atoms of the hydroxamic acid moiety
also coordinate the zinc ion. The hydroxamic acid moiety takes
part in extensive hydrogen-bonding interactions with active site
components: the OH with His500 and Glu497, the NH with
Glu497 and an ordered water molecule (W1), and the carbonyl
with Glu519, Tyr580, and W1 (Figure 2A). In total, the
hydroxamic acid forms 12 metallo or hydrogen bonds with PfA-
M1, in comparison to the 7 interactions made by the
phosphonic acid of the parent compound 1.
PfA-M17 has two catalytic zinc ions which are coordinated by
Asp459, Lys374, Asp379, Asp399, and Glu461. The crystal
structure of PfA-M17:7 shows the hydroxamic acid moiety
coordinates both catalytic zinc ions, as well as forms hydrogen
bonds to ﬁve active site residues: Leu487, Lys374, Asp379,
Asp459, and Lys386. Additionally, the moiety forms a water-
mediated hydrogen bond with Asp399 and interacts with the
active site carbonate ion present in all PfA-M17 structures
(Figure 2B). Overall, the hydroxamic acid of 7 can make 14
potential interactions with PfA-M17, whereas the amino-
phosphonic acid moiety present on 1 makes only 8. While
the hydroxamic acid of 7 and phosphonic acid of 1 are bound in
comparable positions in both PfA-M1 and PfA-M17, the
orientation of the 4-(1H-pyrazol-1-yl)phenyl system, which is
common to both compounds, varies considerably (Figure
2C,D). In the active sites of both enzymes, the 4-(1H-pyrazol-
1-yl)phenyl system of 7 is substantially translated and
additionally rotated compared to that of 1. This places the
biaryl system of 7 in a diﬀerent region of the pockets, stacking
between Tyr575 and Val459 in PfA-M1:7 and Phe398, Met396,
and Gly489 in PfA-M17:7. While few other direct interactions
Figure 2. The hydroxamic acid scaﬀold allows compounds access to the S1′ pocket of PfA-M1 and PfA-M17. (A, B) Stick representation of the
binding mode of compound 7 (purple) to (A) PfA-M1 (gray) and (B) PfA-M17 (beige). Hydrogen bonds are shown as black dashes, key
hydrophobic interactions as orange dashes, zinc ions as black spheres, and ordered water molecules as orange spheres. (C, D) Overlay of the binding
pose of 1dock (teal) and 7 (purple) in PfA-M1 (C) and PfA-M17 (D). The Boc group of 7 probes the S1′ pocket of both enzymes. Active site zinc
and carbonate ions are indicated. (E, F) Overlay of the binding pose of 7 (purple) and 8 (blue) in PfA-M1 (E) and PfA-M17 (F). The binding pose
of compound 7 is dictated by the hydroxamic acid ZBG rather than the 4-(1H-pyrazol-1-yl)phenyl moiety.
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are observed between the 4-(1H-pyrazol-1-yl)phenyl system
and enzyme in either the PfA-M1:7 or PfA-M17:7 structure, the
binding pose of 7 is more reminiscent of that observed for
Bestatin than that of the parent aminophosphonic acid 1.
Bestatin is a Phe-Leu analogue inhibitor based on the transition
state of the proteolysis reaction performed by PfA-M1 and PfA-
M17. When the Bestatin-bound PfA-M1 (PDB ID 3EBH)7 and
PfA-M17 (PDB ID 3KR4)9 structures are overlaid with the
corresponding structures bound to 7, the benzyl group (Phe
side chain) of Bestatin sits in the same position as the 4-(1H-
pyrazol-1-yl)phenyl moiety and the N-Boc group of 7 occupies
the same pocket as the Leu side chain of Bestatin
(Supplementary Figure 3, Supporting Information). It is the
altered binding position of 7 compared to that of 1 that allows
the N-Boc group access to the S1′ pocket. In PfA-M1:1 and
PfA-M17:1, the nitrogen atom of the 2-amino group points
away from the S1′ pocket and forms hydrogen bonds with
Glu463 and Glu319 in PfA-M1:1 and Asp399 in PfA-M17:1,
whereas, in PfA-M1:7 and PfA-M17:7, the corresponding
nitrogen atom (now part of a carbamate group) is positioned to
allow the N-Boc group to access the S1′ pockets (Figure 2C,D).
The altered binding pose conferred by the scaﬀold has diﬀerent
eﬀects on PfA-M1 and PfA-M17 inhibitory activity. The
aminophosphonic acid 1 and its structural analogue from the
hydroxamic acid series, 8, have similar PfA-M1 inhibitory
potencies (Ki = 104 and 74.5 μM, respectively, Table 1),
suggesting that the diﬀerent binding pose does not come at any
cost to binding. In contrast, direct exchange of the phosphonic
acid for the hydroxamic acid ZBG has a detrimental eﬀect on
the PfA-M17 inhibitory activity; 1 has a Ki of 0.011 μM
compared to 86 μM for 8.
The change in binding pose of 1 versus 7 could result from
the geometry of the diﬀerent ZBGs and the nature of their
interaction with the zinc ion(s) and/or steric limitations in the
PfA-M1 and PfA-M17 S1 site for accommodation of the N-Boc
group. To determine whether one or both of these factors
promote the altered binding pose, we docked 8 into both
enzymes (Supplementary Figures 4A and 5A, Supporting
Information). In PfA-M1:8dock, the ligand has a binding pose
similar to that of the ligand in 7 (Figure 2E), with the amine
directed toward the S1′ pocket and forming hydrogen bonds
with the main chain nitrogen and oxygen atoms of Ala461.
Thus, in PfA-M1 it appears that the distinct interaction of the
hydroxamic acid ZBG with the zinc ion may be responsible for
the translated binding pose, relative to that of 1. The structure
of PfA-M17:8dock positions the ligand further from the S1′
pocket toward the S1 pocket (Figure 2F). This suggests that
the N-Boc group present on 7 functions as an S1′ anchor, and
in its absence there may be some mobility of compound
binding that contributes to the reduced aﬃnity of this inhibitor.
Regardless, similarly to PfA-M1:8dock, the binding pose of 8 in
PfA-M17:8dock is similar to that observed for 7, again suggesting
that it is the geometry of the ZBG that dictates the binding
pose of 7, not the N-Boc group. The altered binding pose
observed upon substitution of the phosphonic acid for a
hydroxamic acid suggests that exchange of a ZBG late in the
lead optimization process may not be practical for the retention
of other binding interactions in the active site. However, for this
Figure 3. Structural investigation of the S1′ pocket of PfA-M1 and PfA-M17. (A) Overlay of the binding poses of 7 (purple) and 13d (orange) to
PfA-M1 (gray). PfA-M1 has an enantiomeric preference for (S)-7 and (R)-13d, which allows the tert-butyl groups of both compounds to occupy
similar space and interact with Val493. (B) Overlay of the binding poses of 7 (purple) and 13ddock (orange) to PfA-M17 (beige). Similarly to PfA-
M1, PfA-M17 has an enantiomeric preference for (S)-7 and (R)-13d; however, formation of a hydrogen bond between Gly489 (black dashes) directs
the branched alkanes (tert-butyl in 13d) out of the hydrophobic S1′ cavity. (C) Binding mode of compound 13l (green) to PfA-M1. Hydrogen
bonds are shown as black dashes, the zinc ion is shown as a black sphere, and ordered water molecules are shown as red spheres. (D) Binding poses
of 13l (green) and 13m (gray) in the PfA-M17 cavity. The pocket is ﬂanked by hydrophilic residues at the neck (shown in stick representation), and
a small hydrophobic auxiliary cavity oﬀ the S1′ pocket is visible.
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compound series, the altered binding pose fortuitously oﬀers
the opportunity to exploit further interaction with the S1′
pocket.
The Compound SARs for the S1′ Pocket Are Diﬀerent
for PfA-M1 versus PfA-M17. The consequence of the altered
binding pose brought about by substitution of the series’ ZBG
is that further functionalization of the free amine of 8 oﬀers the
potential to exploit binding interactions with the S1′ pocket
which were previously unavailable to this compound series. In
both PfA-M1:7 and PfA-M17:7, the hydrophobic N-Boc group
sits in the S1′ pocket, in the position occupied by the side chain
of Leu in Bestatin, forming favorable interactions with
hydrophobic residues (Val493 in PfA-M1; Ala460 and Ile547
in PfA-M17) (Figure 2A,B). To probe the steric tolerance of
these pockets, compounds with a range of aliphatic N-acyl
groups (13a−e) as well as substituted N-benzoyl groups (13f−
i) were tested for inhibitory activity at both PfA-M1 and PfA-
M17; their capability to occupy the S1′ pocket was examined
using a combination of crystal and docked structures.
The N-acetyl derivative 13a was found to have opposing
eﬀects on the inhibition of PfA-M1 and PfA-M17. While its
PfA-M1 inhibitory potency is roughly comparable to that of 8
(8, Ki = 74.5 μM; 13a, Ki = 113 μM), it exhibited a
considerable improvement in inhibitory potency for PfA-M17
(8, Ki = 86 μM; 13a, Ki = 0.019 μM) (Table 1). The docked
structure of PfA-M17:13a suggests that the additional carbonyl
group is capable of picking up a hydrogen-bonding interaction
with the backbone amine of Gly489 (Supplementary Figure 5,
Supporting Information). This interaction is also observed in
the structure of Bestatin bound to PfA-M17, suggesting that it is
also common to substrates of the enzyme and therefore is a
good target in inhibitor design.
As the size and branching of the N-acyl group increase from
acetyl (13a) to propionyl (13b), isovaleryl (13c), and pivaloyl
(13d), a corresponding improvement in PfA-M1 inhibitory
potency is observed (Ki = 113, 41.3, 12.3, and 0.7 μM,
respectively, Table 1). This indicates that increasing the steric
bulk of the N-acyl substituent is favorable for binding to the
PfA-M1 S1′ pocket. Docking analysis of each of these
compounds indicates that their binding modes are highly
conserved (Supplementary Figure 4, Supporting Information),
suggesting that the additional space occupied by the larger
substituents within the hydrophobic pocket contributes to
improved binding. Compounds 13d and 7, the most potent
PfA-M1 inhibitors of the series, both bear tert-butyl moieties;
however, 13d bears an amide linker, compared to the
corresponding carbamate linker present on 7. The tert-butyl
moiety of 13d is therefore relatively closer to the ZBG. In the
structure of PfA-M1:7, the tert-butyl group sits deep within the
S1′ pocket and forms hydrophobic contacts with Val493 at the
base. It was therefore not surprising that in the structure of PfA-
M1:13ddock the shorter substituent of 13d does not occupy the
same space as the equivalent group in 7 and is unable to form
hydrophobic interactions with Val493. However, given the lack
of any additional interactions capable of compensating for this
loss, it was curious that both 7 and 13d demonstrated
equivalent inhibitory potencies (Ki values of 0.8 and 0.7 μM,
respectively). We therefore determined the cocrystal structure
of PfA-M1 in complex with 13d (PfA-M1:13d). While a
racemic mixture of the ligand was used for crystallization, only
the R-enantiomer of 13d was observed to bind PfA-M1. This
observation is in contrast to the PfA-M1:7 structure, which
showed only the S-enantiomer bound (Figure 3A). The switch
in enantiomeric preference allows the tert-butyl group of 13d to
occupy a space similar to that of the tert-butyl group of 7 and to
maintain the hydrophobic interactions with Val493. This
adjustment to maintain the interaction with Val493 emphasizes
the importance of the interaction in the S1′ pocket of PfA-M1.
Catalytically, PfA-M17 has a clear preference for bulky
hydrophobic residues;46 therefore, it was anticipated that
compounds bearing increasingly hydrophobic N-acyl moieties
would exhibit improved inhibitory potency. However, in
contrast to the SAR observed with PfA-M1, an increase in
hydrophobic steric bulk from 13a to 13d showed very little
eﬀect on inhibition of PfA-M17 (Table 1). When docked into
the active site (Supplementary Figure 5, Supporting Informa-
tion), it was observed that these compounds all form a
hydrogen bond with Gly489 through the amide carbonyl
oxygen atom. This hydrogen bond orientates short alkyl
substituents out of the main hydrophobic S1′ cavity (Figure
3B), explaining why additional steric presence in this region
does not contribute to binding aﬃnity.
The tolerance of the PfA-M1 S1′ pocket to a variety of
substituted aromatic moieties was then examined with N-
benzoyl-substituted (13f) and N-ﬂuorobenzoyl-substituted
(13g−i) derivatives. Docking analysis showed that the phenyl
group of 13f cannot be accommodated within interaction
distance to Val493 and is instead directed to the solvent,
accounting for the reduced PfA-M1 inhibitory potency.
Although the N-ﬂuorobenzoyl-substituted compounds regained
some of this potency, none inhibited PfA-M1 as well as 7 or
13d. However, beyond the hydrophobic edge of the S1′ pocket
of PfA-M1, the region becomes increasingly solvated within the
large C-terminal channel. This is the putative substrate entry
channel, where both hydrophilic residues and ordered water
molecules are observed. To take advantage of this dual nature
of the pocket, N-aminobenzoyl-substituted derivatives 13l and
13m were also examined. Both compounds demonstrated
moderate inhibitory activity (5.5 and 7.4 μM, respectively,
Table 1), and comparison of the crystal structure of PfA-
M1:13l and the docked structure of PfA-M1:13mdock showed
that the amino substituent is placed in similar positions for both
binding poses, where it is able to form a direct hydrogen bond
with Arg489, in addition to water-mediated hydrogen bonds
with Glu526 (Figure 3C). Elaboration of this moiety to take
advantage of additional hydrogen-bonding partners may lead to
an improved PfA-M1 inhibitory potency of these compounds.
The same series of substituted N-benzoyl compounds (13g−
i and 13l−m) was tested for PfA-M17 inhibitory activity and
was found to eﬀectively recover the loss of potency exhibited by
13f. To determine the structural rationale for this diﬀerence,
both 13l and 13m were cocrystallized with the enzyme. The
two compounds bound with near-identical binding poses, with
only the R-enantiomers of each observed. Similarly to 13a−d at
PfA-M1, these enantiomers allow the N-acyl substituent to
probe deeper into the S1′ pocket. This region of the pocket
contains more hydrophilic residues than the neck of the pocket,
making it more favorable for the electronegative ﬂuoro or polar
amino substituents to occupy (Figure 3D). However, no direct
interactions with the pocket were observed, and little variation
was observed in compound inhibitory potencies. There does
appear to be additional space in the PfA-M17 S1′ pocket,
speciﬁcally a small auxiliary cavity, that is not occupied by 13l−
m (Figure 3D); further extension of this region of the scaﬀold
to better ﬁt the pocket may oﬀer improvements in PfA-M17
inhibition. Conversely, such extension is likely to be
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detrimental to PfA-M1 inhibitor potency, as the PfA-M1 S1′
pocket is less tolerant to aromatic moieties in this region.
The Hydroxamic Acid Compound Series Inhibits the
Growth of P. falciparum 3D7. The described series of
hydroxamic acid-based compounds contains the most potent
dual PfA-M1/PfA-M17 inhibitors described to date. We
therefore determined the ability of these compounds to inhibit
the growth of the asexual erythrocytic stages of Pf-3D7
parasites, utilizing a well-established Pf imaging assay
(Supplementary Figure 6, Supporting Information).47 Brieﬂy,
the parasite number (and thus growth inhibition) was
determined through measurement of the incorporation of the
DNA-intercalating dye 4′,6-diamidino-2-phenylindole into the
parasite nucleus following exposure to the compounds.
Fluorescent images acquired on PerkinElmer’s Opera were
analyzed with a spot detection algorithm using the Acapella
software. Previous potent PfA-M1/PfA-M17 inhibitors Bestatin
and CHR-6768 have been reported to demonstrate inhibitory
potencies between 0.4 and 5 μM for Pf-3D7 parasite growth.
Compounds from our present series inhibit parasite growth
with IC50 values between 0.2 and 0.7 μM (Table 1), with the
variation in potency in general agreement with changes in PfA-
M1/PfA-M17 inhibitory activity. Compound 13d, the most
eﬀective PfA-M1 inhibitor (Ki = 0.7 μM) and one of the more
potent Pf-M17 inhibitors (Ki = 0.028 μM), is the most eﬀective
compound against 3D7 malaria parasites, with an IC50 of 227
nM (Table 1). Although the in vitro inhibitory properties of
compound 7 are comparable to those of 13d, it has an IC50 for
parasite growth of only 783 nM, suggesting that compounds
substituted with the N-Boc group are either less capable of
cellular penetration or less stable than the corresponding N-acyl
derivatives. Compounds 13l and 13m are also highly eﬀective
against the malaria parasites (IC50 values of 233 and 228 nM,
respectively), despite slightly reduced aﬃnity for Pf-M1
compared to 13d (and comparable activity for Pf-M17). This
could be attributed to indirect factors, such as improved cellular
penetration or protozoan cytotoxicity arising from toxic
metabolites produced by the parasite, which has the potential
to be metabolically active during the 3D7 assay. We additionally
screened all of the compounds in the series for cytotoxicity
against human embryonic kidney cells (HEK293) and saw no
observable cytotoxicity at concentrations up to 40 μM
(Supplementary Figure 6). Although we have yet to perform
stability and distribution studies, previous analyses of
hydroxamic acid-based inhibitors suggest that the scaﬀold is
capable of reaching the site of action within cultured
erythrocytes,10 making this a promising scaﬀold for further
development.
Hydroxamate-containing inhibitors of human aminopepti-
dase N have been identiﬁed,48 and Bestatin has undergone
clinical trials as an immunomodulating agent.49,50 Therefore,
the potential for the compounds described here to act upon the
human isoforms of PfA-M1 and/or PfA-M17 in vitro cannot be
discounted. However, the lack of any observed toxicity of our
compounds in HEK293 cells is encouraging for the continued
development of the series. Homologous M1 and M17
aminopeptidases also function as key enzymes in other
parasites51,52 and bacterial pathogens.53,54 This compound
series may therefore have potential applications for the
development of other MAP inhibitors for the treatment of a
range of diseases.
■ CONCLUSIONS
The Pf aminopeptidases M1 and M17 are validated drug targets
for antimalarial agents with a novel mode of action. While
previous inhibitor series demonstrated that cross-inhibition was
possible, diﬀerences in the compound binding proﬁles of the
enzymes meant that compound elaboration tended toward
improved inhibition of one enzyme target at the expense of the
other. We report here the ﬁrst series of compounds capable of
potent dual inhibition of both PfA-M1 and PfA-M17. The series
additionally possesses activity against 3D7 malaria parasites and
no observable cytotoxicity. This hydroxamic acid-based series of
compounds therefore provides extremely attractive lead
molecules for further development into antimalarial com-
pounds with a novel mode of action.
■ EXPERIMENTAL SECTION
Chemistry. Chemicals and solvents were purchased from standard
suppliers and used without further puriﬁcation. Davisil silica gel (40−
63 μm), for ﬂash column chromatography (FCC), was supplied by
Grace Davison Discovery Sciences (Victoria, Australia), and
deuterated solvents were purchased from Cambridge Isotope
Laboratories, Inc. (United States, distributed by Novachem PTY.
Ltd., Victoria, Australia).
Unless otherwise stated, reactions were carried out at ambient
temperature. Reactions were monitored by thin-layer chromatography
on commercially available precoated aluminum-backed plates (Merck
Kieselgel 60 F254). Visualization was by examination under UV light
(254 and 366 nm). General staining was carried out with KMnO4 or
phosphomolybdic acid. A solution of ninhydrin (in ethanol) was used
to visualize primary and secondary amines. A solution of FeCl3 (5% in
0.5 M HCl(aq)) was used to visualize hydroxamic acids. All organic
extracts collected after aqueous workup procedures were dried over
anhydrous Na2SO4 before gravity ﬁltering and evaporation to dryness.
Organic solvents were evaporated in vacuo at ≤40 °C (water bath
temperature). Puriﬁcation using preparative-layer chromatography
(PLC) was carried out on Analtech preparative TLC plates (200
mm × 200 mm × 2 mm).
1H NMR and 13C NMR spectra were recorded on a Bruker Avance
Nanobay III 400 MHz Ultrashield Plus spectrometer at 400.13 and
100.6 MHz, respectively. Chemical shifts (δ) are recorded in parts per
million with reference to the chemical shift of the deuterated solvent.
Coupling constants (J) and carbon−ﬂuorine coupling constants (JCF)
are recorded in hertz and the signiﬁcant multiplicities described as
singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br),
multiplet (m), doublet of doublets (dd), and doublet of triplets (dt).
Spectra were assigned using appropriate correlation spectroscopy
(COSY), distortionless enhanced polarization transfer (DEPT),
heteronuclear single-quantum correlation (HSQC), and heteronuclear
multiple-bond correlation (HMBC) sequences.
LC/MS was run to verify the reaction outcome and purity using
either system A or system B. System A: an Agilent 6100 series single-
quadrupole instrument coupled to an Agilent 1200 series HPLC
instrument. The following buﬀers were used: buﬀer A, 0.1% formic
acid in H2O; buﬀer B, 0.1% formic acid in MeCN. The following
gradient was used with a Phenomenex Luna 3 μM C8(2) 15 × 4.6 mm
column, a ﬂow rate of 0.5 mL/min, and a total run time of 12 min: 0−
4 min 95% buﬀer A and 5% buﬀer B, 4−7 min 0% buﬀer A and 100%
buﬀer B, 7−12 min 95% buﬀer A and 5% buﬀer B. Mass spectra were
acquired in positive and negative ion modes with a scan range of 0−
1000 m/z at 5 V. UV detection was carried out at 254 nm. System B:
an Agilent 6120 series single-quadrupole instrument coupled to an
Agilent 1260 series HPLC instrument. The following buﬀers were
used: buﬀer A, 0.1% formic acid in H2O; buﬀer B, 0.1% formic acid in
MeCN. The following gradient was used with a Poroshell 120 EC-C18
50 × 3.0 mm 2.7 μm column, a ﬂow rate of 0.5 mL/min, and a total
run time of 5 min: 0−1 min 95% buﬀer A and 5% buﬀer B, from 1 to
2.5 min up to 0% buﬀer A and 100% buﬀer B, held at this composition
until 3.8 min, 3.8−4 min 95% buﬀer A and 5% buﬀer B, held until 5
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min at this composition. Mass spectra were acquired in positive and
negative ion modes with a scan range of 100−1000 m/z. UV detection
was carried out at 214 and 254 nm. All retention times (tR) are quoted
in minutes.
Preparative HPLC was performed using an Agilent 1260 Inﬁnity
instrument coupled with a binary preparative pump and Agilent 1260
FC-PS fraction collector using Agilent OpenLAB CDS software
(revision C.01.04) and an Altima 5 μM C8 22 × 250 mm column. The
following buﬀers were used: buﬀer A, H2O; buﬀer B, MeCN. The
sample was run at a gradient of 5% buﬀer B to 100% buﬀer B over 20
min at a ﬂow rate of 20 mL/min. All screening compounds were of
>95% purity unless speciﬁed in the individual monologue.
General Procedure A: Condensation of Methyl 2-(4-(1H-Pyrazol-
1-yl)phenyl)-2-aminoacetate Hydrochloride (11) with Acid Chlor-
ides and Isocyanates. 11 (134 mg, 0.50 mmol) and TEA (0.154 mL,
1.10 mmol, 2.2 equiv in the case of acid chlorides, or 0.077 mL, 0.55
mmol, 1.1 equiv in the case of isocyanates) were dissolved in DCM (3
mL). To this was added the appropriate acid chloride (0.55 mmol, 1.1
equiv), and the mixture was stirred at room temperature for 18 h.
Reaction progress was monitored by TLC (EtOAc/DCM, 1:1). On
completion, the reaction mixtures were diluted with DCM (10 mL)
and washed with water (10 mL). Concentration of the organic layer
aﬀorded the product, which was carried through to the next step with
no further puriﬁcation necessary.
General Procedure B: Direct Aminolysis of Methyl Esters to the
Corresponding Hydroxamic Acids by Sequential Addition of
Reagents. The appropriate methyl ester (0.40−0.55 mmol) and
NH2OH·HCl (139 mg, 2 mmol) were dispersed in MeOH (2 mL) at
room temperature. To this was added in a dropwise fashion 5 M
KOH/MeOH (0.5 mL, 2.5 mmol) further diluted in MeOH (to 10
mL). The mixtures were stirred at room temperature and monitored
by LC/MS analysis. The mixtures were concentrated before
acidiﬁcation with either 1 M HCl(aq) (10 mL) or AcOH/water
(1:1, 10 mL, for more acid sensitive compounds). The aqueous slurry
was then extracted with EtOAc (3 × 10 mL), and the combined
organic layers were washed with brine (10 mL) and then dried of
Na2SO4. Concentration of the organic layers gave the crude product,
which was further puriﬁed by FCC (eluent MeOH/DCM, 0:100 to
10:90).
General Procedure C: Direct Aminolysis of Methyl Esters to the
Corresponding Hydroxamic Acids with Premixing of Reagents
Using Anhydrous MeOH. The appropriate methyl ester (0.40−0.55
mmol) was dissolved in anhydrous MeOH (0.5 mL) at room
temperature in a nitrogen-ﬂushed vessel. In a separate nitrogen-ﬂushed
vial, NH2OH·HCl (139 mg, 2 mmol) and 5 M KOH/anhydrous
MeOH (0.5 mL, 2.5 mmol) were mixed and then sonicated for 30 s.
The resulting suspension was added to the methanolic ester solution
with washings of anhydrous MeOH (1 mL). The mixtures were stirred
at room temperature overnight and monitored by LC/MS analysis.
The mixtures were directly dry-loaded onto Isolute HM-N (Biotage)
before puriﬁcation by FCC (eluent MeOH/DCM, 0:100 to 10:90).
General Procedure D: CDI-Mediated Coupling of Carboxylic
Acids to Hydroxylamine To Give the Corresponding Hydroxamic
Acid. The appropriate carboxylic acid (1 equiv) was dissolved in
anhydrous THF (1−5 mL/mmol) at room temperature under an
atmosphere of nitrogen, and CDI (1.5 equiv) was added. The mixture
was stirred at room temperature for 1 h before addition of NH2OH·
HCl (2 equiv). Stirring was continued at room temperature for 24−48
h before dilution of the mixture with satd NH4Cl(aq) (20 mL) and
then extraction with EtOAc (3 × 20 mL). The combined organic
layers were washed with satd NaHCO3(aq) (20 mL) and brine (20
mL) before concentration under reduced pressure. The resulting crude
product was further puriﬁed by FCC (eluent MeOH/DCM, 0:100 to
10:90).
1-(4-(1H-Pyrazol-1-yl)phenyl)ethan-1-one (3).31 4′-Iodoacetophe-
none (2) (16.15 g, 65.63 mmol), pyrazole (4.92 g, 72.19 mmol, 1.1
equiv), and Cs2CO3 (42.77 g, 131.26 mmol, 2.0 equiv) were placed in
a dry ﬂask under an atmosphere of nitrogen. To this was added dry
DMF (100 mL). The solution was degassed by sonication before
addition of Cu2O (939 mg, 6.56 mmol, 0.1 equiv), and the resulting
solution was heated at 100 °C for 17.5 h. The mixture was cooled
before being diluted with water (400 mL) and then extraction with
EtOAc (4 × 100 mL). The combined organic layers were washed with
brine (100 mL) before being dried over MgSO4, and then the organic
solution was passed through a plug of silica gel. The ﬁltrate was
concentrated under reduced pressure and the resulting residue
dissolved in DCM and passed through a second plug of silica gel,
initially washing with DCM, followed by elution with EtOAc/DCM
(1:1). On concentration of the ﬁltrate, 11.8 g of pale blue solid was
obtained (97%): 1H NMR (CDCl3) δ 8.10−8.04 (m, 2H), 8.01 (d, J =
2.5 Hz, 1H), 7.85−7.79 (m, 2H), 7.77 (d, J = 1.5 Hz, 1H), 6.52 (dd, J
= 2.4/1.9 Hz, 1H), 2.62 (s, 3H); 13C NMR (CDCl3) δ 197.0, 143.4,
142.2, 135.0, 130.1, 127.1, 118.5, 108.7, 26.7; MS (TOF ES+) m/z
C11H11N2O [MH]
+ calcd 187.1, found 187.2; LC/MS tR = 3.50.
2-(4-(1H-Pyrazol-1-yl)phenyl)-2-oxoacetic Acid (4). 3 (11.8 g,
63.37 mmol) and SeO2 (9.6 g, 86.52 mmol, 1.37 equiv) were dispersed
in anhydrous pyridine (300 mL) under an atmosphere of nitrogen gas
and heated under reﬂux at 110 °C for 20 h. LC/MS analysis indicated
almost complete conversion to the desired product, so SeO2 (3.516 g,
31.69 mmol, 0.5 equiv) was added before heating was continued for a
further 5 h. LC/MS analysis indicated the reaction was complete, so
the reaction was cooled to room temperature with stirring overnight.
The mixture was ﬁltered and the ﬁltrate concentrated under reduced
pressure to remove pyridine. The resulting residue was taken up in 2
M HCl(aq) (200 mL) and extracted with EtOAc (300 mL, 2 × 200
mL, 100 mL). The combined organic layers were then extracted with 2
M NaOH(aq) (2 × 100 mL). The combined aqueous extracts were
reacidiﬁed with concd HCl(aq) and reextracted with EtOAc (3 × 200
mL). Finally, the combined organic layers were washed with brine
(100 mL). The combined organic layers were concentrated until
precipitation was observed. At this point, excess hexanes were added to
the ﬂask, and the resultant precipitate was collected by ﬁltration
(vacuum). After drying, 12.58 g (92%) of pale yellow solid was
obtained: 1H NMR (DMSO) δ 14.75 (s, 1H), 8.77−8.65 (m, 1H),
8.17−8.02 (m, 4H), 7.87 (d, J = 1.5 Hz, 1H), 6.65 (dd, J = 2.6/1.7 Hz,
1H); 13C NMR (DMSO) δ 184.3, 163.0, 141.1, 139.6, 128.5, 126.2,
125.7, 115.3, 106.2; MS (TOF ES+) m/z C11H9N2O3 [MH]
+ calcd
217.1, found 217.1; LC/MS tR = 2.67.
2-(4-(1H-Pyrazol-1-yl)phenyl)-2-((tert-butoxycarbonyl)amino)-
acetic Acid (5). 4 (500 mg, 2.31 mmol) was dispersed in dry 1,2-
dichloroethane (20 mL) under an atmosphere of nitrogen. To this was
added N,N-dibenzylamine (913 mg, 0.890 mL, 4.63 mmol, 2 equiv).
The mixture was stirred at room temperature for 5 min before addition
of Na(OAc)3BH (980 mg, 4.63 mmol, 2 equiv). The mixture was then
stirred at room temperature overnight. Workup of a small sample of
reaction mixture in water/EtOAc and LC/MS analysis of each layer
showed starting material and N,N-dibenzylamine partitioned into the
aqueous layer, whereas the EtOAc layer contained product and some
N,N-dibenzylamine. Further Na(OAc)3BH (490 mg, 2.31 mmol, 1
equiv) was added and stirring continued at room temperature
overnight. The mixture was diluted with water (50 mL) and stirred
for 5 min before extraction with EtOAc (3 × 50 mL). The combined
organic layers were then washed with brine (50 mL), with the brine
washings kept separate from the initial water layer. On washing with
brine, precipitation of a white solid occurred. This was collected by
ﬁltration (vacuum) of both organic and brine layers and washing the
collected solid with water. LC/MS analysis of this salt indicated it was
the acetate salt of N,N-dibenzylamine. The organic layers were
concentrated under reduced pressure and further puriﬁed by FCC
(eluent MeOH/DCM, 0:100 to 5:95) to give 89 mg of N-(4-(1H-
pyrazol-1-yl)benzyl)-N-benzyl-1-phenylmethanamine (decarboxylated
product) and 702 mg of desired product contaminated with N,N-
dibenzylamine.
The crude desired product was dissolved in MeOH/water (9:1, 20
mL) before addition of 10% Pd/C (70 mg). The mixture was
hydrogenated (balloon) at room temperature overnight. LC/MS
analysis indicated almost complete monodebenzylation, so water (15
mL) and concd HCl(aq) (1 mL) were added, along with further 10%
Pd/C (70 mg) before continued hydrogenation was continued at
room temperature for 3.5 h. LC/MS analysis after this time indicated
complete N-benzyl deprotection to the primary amine had occurred.
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The mixture was ﬁltered through a bed of Celite (vacuum) with
washings of MeOH before concentration under reduced pressure. The
resulting crude residue was taken up in water (20 mL) and washed
with Et2O (20 mL) before being basiﬁed with satd NaHCO3(aq). The
aqueous layer was washed again with Et2O (20 mL) and the organic
layer discarded. Boc2O (555 mg, 2.54 mmol) was added to the
aqueous layer and the mixture stirred at room temperature for 30 min
before addition of further Boc2O (252 mg, 1.15 mmol) and THF (10
mL). The mixture was stirred at room temperature overnight. After
this time the mixture was carefully acidiﬁed to pH 4 with 2 M HCl(aq)
before extraction with DCM (3 × 50 mL). The combined organic
layers were concentrated under reduced pressure before further
puriﬁcation with FCC (eluent MeOH/DCM, 0:100 to 10:90) to give
410 mg of foamy white solid (56% over three steps): 1H NMR
(DMSO) δ 12.86 (s, 1H), 8.49 (d, J = 2.4 Hz, 1H), 7.81 (d, J = 8.5 Hz,
2H), 7.74 (d, J = 1.5 Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.51 (d, J = 8.6
Hz, 2H), 6.54 (dd, J = 2.3/1.9 Hz, 1H), 5.15 (d, J = 8.2 Hz, 1H), 1.39
(s, 9H); 13C NMR (DMSO) δ 172.2, 155.2, 141.1, 139.2, 135.3, 128.9,
127.8, 118.3, 107.9, 78.5, 57.1, 28.2; MS (TOF ES+) m/z C16H20N3O4
[MH]+ calcd 318.1, found 318.2; LC/MS tR = 3.18.
2-(4-(1H-Pyrazol-1-yl)phenyl)-2-aminoacetic Acid Hydrochloride
(6). 5 (38 mg, 0.12 mmol) was dissolved in DCM (3 mL) before
addition of 4 M HCl/1,4-dioxane (1 mL). The mixture was stirred at
room temperature for 1 h before concentration under reduced
pressure to give 29 mg of white solid (97%): 1H NMR (DMSO) δ
13.96 (s, 1H), 8.91 (s, 3H), 8.55 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 8.7
Hz, 2H), 7.78 (d, J = 1.5 Hz, 1H), 7.63 (d, J = 8.7 Hz, 2H), 6.58 (dd, J
= 2.4/1.8 Hz, 1H), 5.18 (s, 1H); 13C NMR (DMSO) δ 169.7, 141.4,
140.2, 130.9, 129.5, 128.0, 118.6, 108.3, 54.9; MS (TOF ES+) m/z
C11H12N3O2 [MH]
+ calcd 218.1, found 218.1; LC/MS tR = 1.39.
tert-Butyl (1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-
oxoethyl)carbamate (7). 5 (100 mg, 0.32 mmol) was dissolved in
dry THF (1 mL) under an atmosphere of nitrogen at room
temperature. To this was added CDI (76 mg, 0.47 mmol, 1.5
equiv), and the mixture was stirred for 1 h at room temperature.
Hydroxylamine hydrochloride (44 mg, 0.63 mmol, 2 equiv) was
added, and the mixture was then stirred at room temperature
overnight. LC/MS analysis indicated approximately 75% conversion
had taken place, so stirring was continued for a further 3 days. Satd
NH4Cl(aq) (20 mL) was added before extraction with EtOAc (3 × 20
mL). The combined organic layers were then washed with brine (20
mL). After concentration of the organic layers, the crude residue was
further puriﬁed by PLC (NH4OH/MeOH/DCM, 1:10:89), with the
plate being run twice, to give 73 mg of white solid (69%): 1H NMR
(DMSO) δ 10.91 (s, 1H), 9.00 (s, 1H), 8.48 (d, J = 2.4 Hz, 1H), 7.79
(d, J = 8.7 Hz, 2H), 7.73 (d, J = 1.4 Hz, 1H), 7.58−7.45 (m, 3H), 6.54
(dd, J = 2.4/1.8 Hz, 1H), 5.08 (d, J = 8.6 Hz, 1H), 1.38 (s, 9H); 13C
NMR (DMSO) δ 171.7, 166.9, 141.0, 139.1, 134.2, 128.3, 127.8,
118.2, 107.9, 80.5, 54.9, 28.2; MS (TOF ES−) m/z C16H19N4O4 [M −
H]− calcd 331.1, found 331.2; LC/MS tR = 3.02.
2-(4-(1H-Pyrazol-1-yl)phenyl)-2-amino-N-hydroxyacetamide Hy-
drochloride (8). 7 (62 mg, 0.19 mmol) was dissolved in MeOH/DCM
(1:1, 4 mL). To this was added 4 M HCl/1,4-dioxane (2 mL), and the
mixture was stirred at room temperature for 2 h. The mixture was
concentrated under reduced pressure to give 47 mg of hygroscopic
yellow solid. This was further puriﬁed by preparative HPLC to give 13
mg of colorless semisolid (25%): 1H NMR (MeOD) δ 8.29 (d, J = 2.5
Hz, 1H), 7.87 (d, J = 8.6 Hz, 2H), 7.75 (d, J = 1.5 Hz, 1H), 7.64 (d, J
= 8.6 Hz, 2H), 6.56 (dd, J = 2.4/1.9 Hz, 1H), 4.86 (s, 1H); 13C NMR
(MeOD) δ 167.0, 142.7, 142.3, 133.5, 130.3, 129.1, 120.7, 109.3, 55.6;
MS (TOF ES+) m/z C11H13N4O2 [MH]
+ calcd 233.1, found 233.1;
LC/MS tR = 1.49.
2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(benzylamino)acetic Acid (9). 4
(6.00 g, 27.75 mmol) was dispersed in anhydrous 1,2-dichloroethane
(240 mL) under an atmosphere of nitrogen at room temperature. To
this stirred suspension was added benzylamine (5.95 g, 6.06 mL, 55.51
mmol, 2 equiv), and stirring was continued at room temperature for 5
min. Na(OAc)3BH (11.77 g, 55.51 mmol, 2 equiv) was added in
portions, and stirring was continued at room temperature overnight.
The mixture was concentrated and the resulting residue partitioned
between water (200 mL) and EtOAc (100 mL) and stirred for 30 min
at room temperature. The organic solvent was then removed under
reduced pressure and the resulting solid collected by ﬁltration
(vacuum) and washed with water. After drying, 6.45 g (76%) of oﬀ-
white solid was obtained, which was used without further puriﬁcation.
1H NMR analysis proved diﬃcult due to poor solubility in a variety of
solvents, including DMSO, and the obtained spectra were diﬃcult to
interpret due to peak broadness. LC/MS analysis gave a single peak
with the correct mass, so NMR analysis was carried out in the
subsequent step to conﬁrm the structure: MS (TOF ES+) m/z
C18H18N3O2 [MH]
+ calcd 308.1, found 308.2; LC/MS tR = 3.13.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(benzylamino)acetate
(10). 9 (6.34 g, 20.61 mmol) was dispersed in MeOH (200 mL).
To this was added concd H2SO4(aq) (2 mL), and the resulting
mixture was boiled under reﬂux for 24 h before addition of further
concd H2SO4(aq) (1 mL). Heating was continued for a further 24 h
period. LC/MS analysis indicated the reaction was progressing slowly,
so MeOH (100 mL) was added and heating continued for a further 72
h. LC/MS analysis indicated the reaction was complete, so the mixture
was cooled before being concentrated under reduced pressure. The
resulting residue was basiﬁed with satd NaHCO3(aq) (250 mL) before
extraction with DCM (3 × 100 mL). The combined organic layers
were concentrated under reduced pressure and the resulting residue
puriﬁed by FCC (eluent EtOAc/PE, 0:100 to 30:70, with a plateau at
15:85) to give 5.90 g (89%) of pale yellow oil: 1H NMR (CDCl3) δ
7.96−7.90 (m, 1H), 7.90−7.70 (m, 3H), 7.69−7.53 (m, 2H), 7.49−
7.28 (m, 5H), 6.54−6.40 (m, 1H), 4.70−4.45 (m, 1H), 4.44−4.02 (m,
1H), 3.95−3.75 (m, 2H), 3.75−3.64 (m, 2H); 13C NMR (CDCl3) δ
172.2, 141.7, 140.0, 139.9, 138.1, 130.1, 129.53, 129.4, 129.0, 128.5,
126.9, 119.7, 108.2, 63.6, 53.2, 52.7; MS (TOF ES+) m/z C19H20N3O2
[MH]+ calcd 322.2, found 322.2; LC/MS tR = 3.21.
1H/13C NMR
spectra indicate multiple conformational states.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-aminoacetate Hydro-
chloride (11). 10 (6.047 g, 18.82 mmol) was dissolved in MeOH
(250 mL) and concd (32%) HCl(aq) (4 mL) before addition of 10%
Pd/C (600 mg, 0.1 equiv by weight). The mixture was hydrogenated
(balloon) at room temperature for 48 h. LC/MS analysis indicated
complete conversion had taken place. The mixture was ﬁltered
through a bed of Celite with washings of MeOH. The ﬁltrate was
concentrated under reduced pressure and the resulting residue
dispersed in satd NaHCO3(aq) before extraction with DCM (3 ×
100 mL). The combined organic layers were concentrated under
reduced pressure to give 5.507 g of crude product. This was taken up
in Et2O/DCM before addition of a solution of 1 M HCl/Et2O (25
mL). The resulting solution was stirred at room temperature for 30
min before being diluted with Et2O, and the resulting precipitate was
ﬁltered to give 4.407 g (87%) of white amorphous solid: 1H NMR
(DMSO) δ 9.13 (d, J = 3.3 Hz, 3H), 8.56 (d, J = 2.3 Hz, 1H), 7.94 (d,
J = 8.7 Hz, 2H), 7.78 (d, J = 1.5 Hz, 1H), 7.63 (d, J = 8.7 Hz, 2H),
6.58 (dd, J = 2.4/1.8 Hz, 1H), 5.36 (q, J = 5.0 Hz, 1H), 3.73 (s, 3H);
13C NMR (DMSO) δ 168.8, 141.5, 140.4, 130.1, 129.7, 128.0, 118.6,
108.3, 54.7, 53.3; MS (TOF ES+) m/z C12H14N3O2 [MH]
+ calcd
232.1, found 232.2; LC/MS tR = 3.02.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-acetamidoacetate (12a).
Acetyl chloride (0.039 mL, 0.55 mmol, 1.1 equiv) was reacted as
described in general procedure A. After 24 h, further acetyl chloride
(0.4 equiv) and triethylamine (0.5 equiv) were added, and stirring was
continued for 24 h prior to workup to give 128 mg (93%) of oﬀ-white
solid: 1H NMR (CDCl3) δ 7.91 (d, J = 2.4 Hz, 1H), 7.73 (d, J = 1.5
Hz, 1H), 7.72−7.65 (m, 2H), 7.51−7.41 (m, 2H), 6.57 (d, J = 6.7 Hz,
1H), 6.48 (dd, J = 2.4, 1.9 Hz, 1H), 5.62 (d, J = 7.1 Hz, 1H), 3.75 (s,
3H), 2.31 (s, 1H), 2.06 (s, 3H); 13C NMR (CDCl3) δ 171.4, 169.5,
141.4, 140.3, 135.0, 128.6, 127.0, 119.8, 108.0, 56.0, 53.1, 23.2; MS
(TOF ES+) m/z C14H16N3O3 [MH]
+ calcd 274.1, found 274.1; LC/
MS tR = 3.30.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-propionamidoacetate
(12b). Propionyl chloride (0.048 mL, 0.55 mmol, 1.1 equiv) was
reacted as described in general procedure A to give 135 mg (93%) of
pale pink solid: 1H NMR (CDCl3) δ 7.95−7.89 (m, 1H), 7.75 (d, J =
1.5 Hz, 1H), 7.73−7.66 (m, 2H), 7.50−7.42 (m, 2H), 6.52 (d, J = 6.7
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Hz, 1H), 6.48 (dd, J = 2.4, 1.9 Hz, 1H), 5.62 (d, J = 7.0 Hz, 1H), 3.75
(s, 3H), 2.30 (dd, J = 7.6/3.1 Hz, 2H), 2.23 (s, 1H), 1.17 (t, J = 7.6
Hz, 3H); 13C NMR (CDCl3) δ 173.2, 171.5, 141.3, 140.2, 135.2,
128.6, 127.1, 119.8, 108.0, 55.9, 53.1, 29.5, 9.6; MS (TOF ES+) m/z
C15H18N3O3 [MH]
+ calcd 288.1, found 288.2; LC/MS tR = 3.40.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-isobutyramidoacetate
(12c). Isobutyryl chloride (0.058 mL, 0.55 mmol, 1.1 equiv) was
reacted as described in general procedure A to give 129 mg (85%) of
oﬀ-white solid: 1H NMR (CDCl3) δ 7.95−7.90 (m, 1H), 7.74 (d, J =
1.7 Hz, 1H), 7.73−7.66 (m, 2H), 7.50−7.41 (m, 2H), 6.54 (d, J = 6.7
Hz, 1H), 6.48 (dd, J = 2.4/1.9 Hz, 1H), 5.60 (d, J = 6.9 Hz, 1H), 3.75
(s, 3H), 2.46 (hept, J = 6.9 Hz, 1H), 2.33 (s, 1H), 1.19 (d, J = 6.8 Hz,
3H), 1.15 (d, J = 6.9 Hz, 3H); 13C NMR (CDCl3) δ 176.4, 171.5,
141.4, 140.2, 135.2, 128.5, 127.0, 119.8, 108.0, 55.8, 53.1, 35.5, 31.1,
19.6, 19.5; MS (TOF ES+) m/z C16H20N3O3 [MH]
+ calcd 302.1,
found 302.2; LC/MS tR = 3.49.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-pivalamidoacetate (12d).
Pivaloyl chloride (0.068 mL, 0.55 mmol, 1.1 equiv) was reacted as
described in general procedure A to give 152 mg (96%) of oﬀ-white
solid: 1H NMR (CDCl3) δ 7.92 (d, J = 2.4 Hz, 1H), 7.76 (d, J = 1.6
Hz, 1H), 7.70 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.5 Hz, 2H), 6.72 (d, J
= 6.3 Hz, 1H), 6.56−6.40 (m, 1H), 5.56 (d, J = 6.6 Hz, 1H), 3.75 (s,
3H), 2.24 (s, 1H), 1.23 (s, 9H); 13C NMR (CDCl3) δ 178.0, 171.6,
141.3, 140.2, 135.3, 128.5, 127.0, 119.9, 108.0, 56.0, 53.1, 38.8, 27.5;
MS (TOF ES+) m/z C17H22N3O3 [MH]
+ calcd 316.2, found 316.2;
LC/MS tR = 3.63.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(3-tert-butylureido)-
acetate (12e). tert-Butyl isocyanate (0.063 mL, 0.55 mmol, 1.1
equiv) was reacted as described in general procedure A to give 150 mg
(91%) of oﬀ-white foamy solid: 1H NMR (CDCl3) δ 7.94−7.89 (m,
1H), 7.73 (d, J = 1.5 Hz, 1H), 7.70−7.64 (m, 2H), 7.49−7.41 (m,
2H), 6.47 (dd, J = 2.4/1.9 Hz, 1H), 5.49 (s, 1H), 3.73 (s, 3H), 3.39 (s,
2H), 1.32 (s, 9H); 13C NMR (CDCl3) δ 172.1, 156.3, 141.1, 139.9,
135.9, 128.5, 127.3, 119.9, 108.1, 77.5, 77.4, 77.2, 76.8, 56.7, 53.1, 51.2,
29.5; MS (TOF ES+) m/z C17H23N4O3 [MH]
+ calcd 331.2, found
331.2; LC/MS tR = 3.57.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-benzamidoacetate (12f).
Benzoyl chloride (0.064 mL, 0.55 mmol, 1.1 equiv) was reacted as
described in general procedure A to give 166 mg (99%) of oﬀ-white
solid: 1H NMR (CDCl3) δ 7.92 (d, J = 2.2 Hz, 1H), 7.87−7.80 (m,
2H), 7.75 (d, J = 1.5 Hz, 1H), 7.74−7.69 (m, 2H), 7.59−7.50 (m,
3H), 7.49−7.41 (m, 2H), 6.49 (dd, J = 2.4/1.9 Hz, 1H), 5.81 (d, J =
6.7 Hz, 1H), 3.79 (s, 3H), 2.34 (s, 1H); 13C NMR (CDCl3) δ 171.4,
166.7, 141.2, 140.1, 135.2, 133.6, 132.2, 128.8, 128.7, 127.3, 127.2,
119.9, 108.1, 56.4, 53.3; MS (TOF ES+) m/z C19H18N3O3 [MH]
+
calcd 336.1, found 336.1; LC/MS tR = 3.62.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(2-ﬂuorobenzamido)-
acetate (12g). 2-Fluorobenzoyl chloride (0.066 mL, 0.55 mmol, 1.1
equiv) was reacted as described in general procedure A. The reaction
was complete within 90 min and, after workup, gave 186 mg of oﬀ-
white solid (quantitative): 1H NMR (CDCl3) δ 8.07 (ddd, J = 7.9/7.9/
1.8 Hz, 1H), 7.92 (dd, J = 2.5/0.5 Hz, 1H), 7.89 (dd, J = 6.9/6.3 Hz,
1H), 7.75 (d, J = 1.5 Hz, 1H), 7.74−7.69 (m, 2H), 7.60−7.54 (m,
2H), 7.50 (dddd, J = 8.3/7.3/5.2/1.9 Hz, 1H), 7.28−7.23 (m, 1H),
7.16 (ddd, J = 12.1/8.3/0.9 Hz, 1H), 6.49 (dd, J = 2.4/1.9 Hz, 1H),
5.81 (dd, J = 6.4/1.8 Hz, 1H), 3.79 (s, 3H), 2.09 (s, 1H); 19F NMR
(376 MHz, CDCl3) δ −112.78; 13C NMR (CDCl3) δ 171.1, 167.0,
161.1 (d, JCF = 248.2 Hz), 141.4, 140.4, 134.8, 134.0 (d, JCF = 9.4 Hz),
132.2 (d, JCF = 1.9 Hz), 128.7, 126.9, 125.0 (d, JCF = 3.2 Hz), 124.8,
119.8, 116.3 (d, JCF = 24.7 Hz), 108.0, 56.8, 53.2; MS (TOF ES
+) m/z
C19H17FN3O3 [MH]
+ calcd 354.1, found 354.2; LC/MS tR = 3.68.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(3-ﬂuorobenzamido)-
acetate (12h). 3-Fluorobenzoic acid (74 mg, 0.53 mmol, 1.05
equiv) and HCTU (228 mg, 0.55 mmol, 1.1 equiv) were dissolved in
DMF (0.5 mL) at room temperature. DIPEA (0.193 mL, 1.10 mmol,
2.2 equiv) was added, followed by 11 (134 mg, 0.50 mmol) and DCM
(0.5 mL). The mixture was stirred at room temperature for 135 min
before LC/MS analysis indicated complete conversion had taken
place. Satd NaHCO3(aq)/water (1:1) (20 mL) was added and the
aqueous slurry extracted with Et2O (3 × 10 mL). The combined
organic layers were washed with brine (10 mL) before being
concentrated under reduced pressure to give 189 mg (100%) of pale
brown solid, which was used without further puriﬁcation: 1H NMR
(CDCl3) δ 7.92 (d, J = 2.2 Hz, 1H), 7.74 (d, J = 1.5 Hz, 1H), 7.73−
7.69 (m, 2H), 7.65−7.50 (m, 4H), 7.43 (ddd, J = 8.0/8.0/5.5 Hz, 1H),
7.23 (dddd, J = 8.3/8.3/2.6/1.0 Hz, 2H), 6.48 (dd, J = 2.4/1.9 Hz,
1H), 5.78 (d, J = 6.7 Hz, 1H), 3.80 (s, 3H), 2.20 (s, 1H); 19F NMR
(376 MHz, CDCl3) δ −111.49; 13C NMR (CDCl3) δ 171.2, 164.2,
164.0 (d, JCF = 279.3 Hz), 141.1, 140.0, 135.9, 135.1, 130.5 (d, JCF =
7.9 Hz), 128.7, 127.3, 122.7 (d, JCF = 3.1 Hz), 120.0, 119.2 (d, JCF =
21.2 Hz), 114.8 (d, JCF = 23.0 Hz), 108.1, 56.5, 53.4; MS (TOF ES
+)
m/z C19H17FN3O3 [MH]
+ calcd 354.1, found 354.2; LC/MS tR = 3.66.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(4-ﬂuorobenzamido)-
acetate (12i). 4-Fluorobenzoic acid (74 mg, 0.53 mmol, 1.05 equiv)
was coupled to 11 (134 mg, 0.50 mmol) according to the procedure
described for the synthesis of 12h to give 214 mg (100%) of pale
brown solid, which was used without further puriﬁcation: 1H NMR
(CDCl3) δ 7.94−7.91 (m, 1H), 7.88−7.81 (m, 2H), 7.74 (d, J = 1.7
Hz, 1H), 7.73−7.68 (m, 2H), 7.57−7.51 (m, 2H), 7.16−7.09 (m, 2H),
6.58−6.33 (m, 1H), 5.78 (d, J = 6.7 Hz, 1H), 3.79 (s, 3H), 2.27 (s,
1H); 19F NMR (376 MHz, CDCl3) δ −107.24; 13C NMR (CDCl3) δ
171.4, 165.6, 165.3 (d, JCF = 284.8 Hz), 141.4, 138.9, 135.0, 131.9,
129.7 (d, JCF = 9.0 Hz), 128.7, 127.0, 119.9, 115.9 (d, JCF = 22.0 Hz),
108.1, 56.5, 53.3; MS (TOF ES+) m/z C19H17FN3O3 [MH]
+ calcd
354.1, found 354.2; LC/MS tR = 3.64.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(3-nitrobenzamido)-
acetate (12j). 3-Nitrobenzoyl chloride (102 mg, 0.55 mmol, 1.1
equiv) was reacted as described in general procedure A. After 4 h,
further 3-nitrobenzoyl chloride (27 mg, 0.3 equiv) and TEA (0.035
mL, 0.5 equiv) were added, and stirring was continued for 24 h. LC/
MS analysis indicated incomplete conversion, so 3-nitrobenzoyl
chloride (46 mg, 0.5 equiv) and TEA (0.035 mL, 0.5 equiv) were
added again, and stirring was continued for a further 24 h prior to
workup to give 188 mg (99%) of pink solid: 1H NMR (CDCl3) δ 8.66
(dd, J = 1.9/1.9 Hz, 1H), 8.39 (ddd, J = 8.2/2.2/1.0 Hz, 1H), 8.22−
8.15 (m, 1H), 7.93 (dd, J = 2.5/0.4 Hz, 1H), 7.77−7.71 (m, 3H), 7.67
(dd, J = 7.9/7.9 Hz, 1H), 7.58−7.51 (m, 2H), 7.37 (d, J = 6.0 Hz, 1H),
6.49 (dd, J = 2.4/1.9 Hz, 1H), 5.80 (d, J = 6.7 Hz, 1H), 3.81 (s, 3H);
13C NMR (CDCl3) δ 171.1, 164.3, 148.4, 141.3, 140.2, 135.2, 134.6,
133.3, 130.1, 128.8, 127.2, 126.7, 122.3, 120.0, 108.2, 77.5, 77.4, 77.2,
76.8, 56.7, 53.5; MS (TOF ES+) m/z C19H17N4O5 [MH]
+ calcd 381.1,
found 381.2; LC/MS tR = 3.66.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(4-nitrobenzamido)-
acetate (12k). 4-Nitrobenzoyl chloride (102 mg, 0.55 mmol, 1.1
equiv) was reacted as described in general procedure A. After 4 h,
additional 4-nitrobenzoyl chloride (27 mg, 0.3 equiv) and TEA (0.035
mL, 0.5 equiv) were added, and stirring was continued for 24 h prior
to workup. In this case, the mixture was diluted with EtOAc (20 mL)
and then washed with water (10 mL) and satd NaHCO3(aq) (10 mL).
The organic layers were concentrated under reduced pressure to give
162 mg (85%) of pink solid: 1H NMR (CDCl3) δ 8.36−8.28 (m, 2H),
8.05−7.96 (m, 2H), 7.93 (d, J = 2.4 Hz, 1H), 7.78 (d, J = 1.7 Hz, 1H),
7.74 (d, J = 8.6 Hz, 2H), 7.55 (d, J = 8.5 Hz, 2H), 6.56−6.46 (m, 1H),
5.79 (d, J = 6.6 Hz, 1H), 3.81 (s, 3H); 13C NMR (CDCl3) δ 171.2,
165.6, 150.0, 141.5, 139.1, 137.4, 135.0, 128.7, 128.6, 127.0, 124.1,
119.9, 108.2, 56.7, 53.5; MS (TOF ES+) m/z C19H17N4O5 [MH]
+
calcd 381.1, found 381.2; LC/MS tR = 3.65.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(3-aminobenzamido)-
acetate (12l). 12j (115 mg, 0.30 mmol) was dispersed in MeOH
(20 mL) and 10% Pd/C (10 mg) added under an atmosphere of
nitrogen. The reaction ﬂask was sealed before evacuation and
replacement of the atmosphere with hydrogen. The mixture was
then stirred under an atmosphere of hydrogen (balloon) for 1 h at
room temperature. LC/MS analysis after this time indicated that
complete conversion had taken place, so the mixture was ﬁltered
through a bed of Celite with washings of MeOH. The ﬁltrate was
concentrated under reduced pressure to give 102 mg (97%) of oﬀ-
white glassy solid, which was used without further puriﬁcation: 1H
NMR (CDCl3) δ 7.89 (d, J = 1.8 Hz, 1H), 7.70 (s, 1H), 7.66 (d, J =
8.4 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 7.42−7.30 (m, 1H), 7.23−7.04
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(m, 3H), 6.81 (s, 1H), 6.44 (s, 1H), 5.76 (d, J = 6.8 Hz, 1H), 4.16−
3.53 (m, 5H); 13C NMR (CDCl3) δ 171.4, 167.1, 147.0, 141.4, 140.3,
134.8, 134.6, 129.6, 128.6, 126.9, 119.6, 118.5, 116.7, 113.9, 107.9,
56.4, 53.1; MS (TOF ES+) m/z C19H19N4O3 [MH]
+ calcd 351.1,
found 351.2; LC/MS tR = 3.37.
Methyl 2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(4-aminobenzamido)-
acetate (12m). 12k (62 mg, 0.16 mmol) was hydrogenated according
to the procedure described for the synthesis of 12l to give 51 mg
(91%) of brown solid: 1H NMR (CDCl3) δ 8.85−7.06 (m, 11H),
6.97−6.21 (m, 3H), 5.82 (s, 1H), 3.85 (s, 3H); 13C NMR (CDCl3) δ
171.6, 166.5, 150.3, 141.4, 140.2, 135.1, 129.1, 128.6, 126.9, 122.7,
119.6, 114.2, 107.9, 56.3, 53.1; MS (TOF ES+) m/z C19H19N4O3
[MH]+ calcd 351.1, found 351.2; LC/MS tR = 3.42.
2-(4-(1H-Pyrazol-1-yl)phenyl)-2-acetamido-N-hydroxyacetamide
(13a). 12a (120 mg, 0.44 mmol) was converted to the corresponding
hydroxamic acid according to general procedure B. The reaction was
complete after 30 min. After puriﬁcation, 69 mg (57%) of oﬀ-white
solid was obtained: 1H NMR (DMSO) δ 11.01 (s, 1H), 9.01 (s, 1H),
8.69 (d, J = 8.4 Hz, 1H), 8.58−8.27 (m, 1H), 7.90−7.76 (m, 2H), 7.73
(d, J = 1.4 Hz, 1H), 7.49 (d, J = 8.6 Hz, 2H), 6.54 (dd, J = 2.4/1.8 Hz,
1H), 5.40 (d, J = 8.4 Hz, 1H), 1.91 (s, 3H); 13C NMR (DMSO) δ
169.0, 166.6, 141.0, 139.1, 136.8, 128.1, 127.8, 118.3, 107.9, 53.2, 22.4;
MS (TOF ES+) m/z C13H15N4O3 [MH]
+ calcd 275.1, found 275.2;
LC/MS tR = 3.07.
N-(1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-
propionamide (13b). 12b (126 mg, 0.44 mmol) was converted to the
corresponding hydroxamic acid according to general procedure B. The
reaction was complete after 4 h. After puriﬁcation, 44 mg (35%) of oﬀ-
white solid was obtained: 1H NMR (DMSO) δ 11.01 (d, J = 1.2 Hz,
1H), 9.02 (d, J = 1.3 Hz, 1H), 8.60 (d, J = 8.4 Hz, 1H), 8.47 (d, J = 2.1
Hz, 1H), 7.89−7.76 (m, 2H), 7.73 (d, J = 1.5 Hz, 1H), 7.50 (d, J = 8.6
Hz, 2H), 6.54 (dd, J = 2.4/1.8 Hz, 1H), 5.41 (d, J = 8.4 Hz, 1H), 2.22
(q, J = 7.5 Hz, 2H), 0.98 (t, J = 7.6 Hz, 3H); 13C NMR (DMSO) δ
172.7, 166.6, 141.0, 139.0, 136.8, 128.1, 127.8, 118.3, 107.9, 53.1, 28.0,
9.83; MS (TOF ES+) m/z C14H17N4O3 [MH]
+ calcd 289.1, found
289.2; LC/MS tR = 3.14.
N-(1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-
isobutyramide (13c). 12c (122 mg, 0.40 mmol) was converted to the
corresponding hydroxamic acid according to general procedure B.
After 22 h of stirring, only partial conversion had occurred, so
NH2OH·HCl (70 mg, 1 mmol) and 5 M KOH/MeOH (0.5 mL, 2.5
mmol) were added, and stirring was continued at room temperature
for a further 24 h. After puriﬁcation, 71 mg (59%) of oﬀ-white solid
was obtained: 1H NMR (DMSO) δ 11.01 (d, J = 1.2 Hz, 1H), 9.03 (d,
J = 1.3 Hz, 1H), 8.56 (d, J = 8.5 Hz, 1H), 8.51−8.43 (m, 1H), 7.88−
7.77 (m, 2H), 7.73 (d, J = 1.6 Hz, 1H), 7.50 (d, J = 8.6 Hz, 2H), 6.54
(dd, J = 2.4/1.8 Hz, 1H), 5.40 (d, J = 8.4 Hz, 1H), 2.64 (hept, J = 6.8
Hz, 1H), 1.00 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H); 13C NMR
(DMSO) δ 175.9, 166.6, 141.0, 139.0, 136.9, 128.0, 127.8, 118.3,
107.9, 52.9, 33.3, 19.6, 19.5; MS (TOF ES+) m/z C15H19N4O3 [MH]
+
calcd 303.1, found 303.2; LC/MS tR = 3.22.
N-(1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-
pivalamide (13d). 12d (143 mg, 0.46 mmol) was converted to the
corresponding hydroxamic acid according to general procedure B.
After 22 h of stirring, only partial conversion had occurred, so
NH2OH·HCl (70 mg, 1 mmol) and 5 M KOH/MeOH (0.5 mL, 2.5
mmol) were added, and stirring was continued at room temperature
for a further 24 h. At this point additional NH2OH·HCl (139 mg, 2
mmol) and 5 M KOH/MeOH (0.6 mL, 3.0 mmol) were added, and
stirring was continued for a further 24 h. After puriﬁcation, 100 mg
(68%) of glassy solid was obtained: 1H NMR (DMSO) δ 11.02 (s,
1H), 9.08 (s, 1H), 8.47 (d, J = 2.4 Hz, 1H), 7.84−7.75 (m, 2H), 7.73
(d, J = 1.4 Hz, 1H), 7.51 (d, J = 8.6 Hz, 2H), 6.74−6.38 (m, 1H), 5.41
(d, J = 8.1 Hz, 1H), 1.15 (s, J = 8.2 Hz, 9H); 13C NMR (DMSO) δ
176.9, 166.6, 141.0, 139.0, 136.9, 127.9, 127.8, 118.3, 107.9, 53.2, 38.2,
27.2; MS (TOF ES+) m/z C16H21N4O3 [MH]
+ calcd 317.2, found
317.2; LC/MS tR = 3.30.
2-(4-(1H-Pyrazol-1-yl)phenyl)-2-(3-tert-butylureido)-N-hydroxya-
cetamide (13e). 12e (147 mg, 0.44 mmol) was converted to the
corresponding hydroxamic acid according to general procedure B.
After 4.5 h, starting material had disappeared by LC/MS, with the
formation of the desired product and corresponding carboxylic acid
(hydrolysis product). After FCC puriﬁcation (eluent MeOH/DCM,
0:100 to 10:90), the major product isolated was found to be 2-(4-(1H-
pyrazol-1-yl)phenyl)-2-(3-tert-butylureido)acetic acid (44 mg, 32%).
This was directly converted to the desired hydroxamic acid according
to general procedure D using CDI (3 equiv), NH2OH·HCl (4 equiv),
and anhydrous THF (2 mL). After puriﬁcation, 11 mg (8% based on
ester, 24% based on acid) of oﬀ-white solid was obtained: 1H NMR
(DMSO) δ 11.00 (s, 1H), 9.00 (s, 1H), 8.45 (d, J = 2.5 Hz, 1H), 7.80
(d, J = 8.6 Hz, 2H), 7.73 (d, J = 1.6 Hz, 1H), 7.42 (d, J = 8.6 Hz, 2H),
6.65 (d, J = 8.6 Hz, 1H), 6.59−6.46 (m, 1H), 6.12 (s, 1H), 5.18 (d, J =
8.6 Hz, 1H), 1.20 (s, 9H); 13C NMR (DMSO) δ 167.3, 156.2, 140.9,
138.9, 138.4, 127.7, 127.5, 118.3, 107.8, 53.3, 49.1, 29.2; MS (TOF
ES−) m/z C16H20N5O3 [M − H]− calcd 330.2, found 330.2; LC/MS tR
= 3.32.
N-(1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-
benzamide (13f). 12f (161 mg, 0.48 mmol) was converted to the
corresponding hydroxamic acid according to general procedure B.
After 22 h of stirring, only partial conversion had occurred, so
NH2OH·HCl (70 mg, 1 mmol) and 5 M KOH/MeOH (0.5 mL, 2.5
mmol) were added, and stirring was continued at room temperature
for a further 24 h. At this point additional NH2OH·HCl (139 mg, 2
mmol) and 5 M KOH/MeOH (0.6 mL, 3.0 mmol) were added, and
stirring was continued for a further 24 h. After FCC puriﬁcation
(eluent MeOH/DCM, 0:100 to 10:90), the major product isolated
was found to be 2-(4-(1H-pyrazol-1-yl)phenyl)-2-benzamidoacetic
acid (99 mg, 65%). This was directly converted to the desired
hydroxamic acid according to general procedure D using CDI (3
equiv), NH2OH·HCl (4 equiv), and anhydrous THF (5 mL). After
puriﬁcation, 7 mg (4% based on ester, 7% based on acid) of oﬀ-white
solid was obtained: 1H NMR (MeOD) δ 8.23 (dd, J = 2.5/0.4 Hz,
1H), 7.92−7.85 (m, 2H), 7.81−7.70 (m, 3H), 7.68−7.61 (m, 2H),
7.60−7.51 (m, 1H), 7.51−7.41 (m, 2H), 6.53 (dd, J = 2.5, 1.9 Hz,
1H), 5.68 (s, 1H); 13C NMR (MeOD) δ 169.9, 169.3, 142.3, 141.3,
137.2, 135.0, 133.0, 129.9, 129.6, 129.1, 128.7, 120.5, 108.9, 56.2; MS
(TOF ES+) m/z C18H17N4O3 [MH]
+ calcd 337.1, found 337.2; LC/
MS tR = 3.30.
N-(1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-
2-ﬂuorobenzamide (13g). 12g (168 mg, 0.48 mmol) was converted
to the corresponding hydroxamic acid according to general procedure
B. The reaction was complete after 2 h. After puriﬁcation, 100 mg
(59%) of oﬀ-white solid was obtained: 1H NMR (DMSO) δ 11.12 (d,
J = 1.2 Hz, 1H), 9.14 (d, J = 1.3 Hz, 1H), 8.90 (dd, J = 7.9/4.0 Hz,
1H), 8.54−8.39 (m, 1H), 7.91−7.77 (m, 2H), 7.74 (d, J = 1.4 Hz,
1H), 7.65 (ddd, J = 7.7/7.7/1.8 Hz, 1H), 7.62−7.49 (m, 3H), 7.35−
7.24 (m, 2H), 6.54 (dd, J = 2.4/1.8 Hz, 1H), 5.58 (d, J = 7.9 Hz, 1H);
19F NMR (376 MHz, DMSO) δ −113.8; 13C NMR (DMSO) δ 166.2,
163.1, 159.3 (d, JCF = 205.6 Hz), 141.0, 139.2, 136.3, 132.9 (d, JCF =
8.5 Hz), 130.4 (d, JCF = 2.6 Hz), 128.2, 127.8, 124.5 (d, JCF = 3.3 Hz),
121.7 (d, JCF = 30.4 Hz), 118.4, 116.1 (d, JCF = 22.8 Hz), 107.9, 53.9;
MS (TOF ES−) m/z C18H14FN4O3 [M − H]− calcd 353.1, found
353.1; LC/MS tR = 3.41.
N-(1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-
3-ﬂuorobenzamide (13h). 12h (172 mg, 0.49 mmol) was converted
to the corresponding hydroxamic acid according to general procedure
B. The reaction was complete after 2 h. After puriﬁcation, 101 mg
(58%) of oﬀ-white solid was obtained: 1H NMR (DMSO) δ 11.06 (d,
J = 1.2 Hz, 1H), 9.11 (d, J = 8.0 Hz, 1H), 9.06 (d, J = 1.3 Hz, 1H),
8.53−8.44 (m, 1H), 7.88−7.81 (m, 2H), 7.81−7.71 (m, 3H), 7.61 (d, J
= 8.6 Hz, 2H), 7.52 (ddd, J = 8.1/8.1/6.1 Hz, 1H), 7.45−7.35 (m,
1H), 6.55 (dd, J = 2.4/1.8 Hz, 1H), 5.63 (d, J = 8.0 Hz, 1H); 19F NMR
(376 MHz, DMSO) δ −113.1; 13C NMR (DMSO) δ 166.4, 165.0,
164.2 (d, JCF = 225.0 Hz), 141.0, 139.2, 136.1 (d, JCF = 6.9 Hz), 136.0,
130.3 (d, JCF = 7.8 Hz), 128.7, 127.8, 124.0 (d, JCF = 2.5 Hz), 118.4 (d,
JCF = 21.3 Hz), 118.2, 114.6 (d, JCF = 23.1 Hz), 107.9, 54.3; MS (TOF
ES+) m/z C18H16FN4O3 [MH]
+ calcd 355.1, found 355.2; LC/MS tR =
3.35.
N-(1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-
4-ﬂuorobenzamide (13i). 12i (193 mg, 0.55 mmol) was converted to
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the corresponding hydroxamic acid according to general procedure B.
The reaction was complete after overnight stirring. After puriﬁcation,
97 mg (50%) of oﬀ-white solid was obtained: 1H NMR (DMSO) δ
11.05 (s, 1H), 9.05 (s, 1H), 9.02 (d, J = 8.1 Hz, 1H), 8.49 (d, J = 2.3
Hz, 1H), 8.09−7.90 (m, 2H), 7.83 (d, J = 8.7 Hz, 2H), 7.74 (d, J = 1.5
Hz, 1H), 7.61 (d, J = 8.6 Hz, 2H), 7.36−7.23 (m, 2H), 6.63−6.47 (m,
1H), 5.63 (d, J = 8.0 Hz, 1H); 19F NMR (376 MHz, DMSO) δ
−109.1; 13C NMR (DMSO) δ 167.0 (d, JCF = 230.6 Hz), 166.5, 165.3,
141.0, 139.2, 136.2, 130.5 (d, JCF = 8.9 Hz), 130.3, 128.6, 127.8, 118.2,
115.1 (d, JCF = 21.7 Hz), 108.1−107.6 (m), 54.3; MS (TOF ES+) m/z
C18H16FN4O3 [MH]
+ calcd 355.1, found 355.2; LC/MS tR = 3.36.
N-(1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-
3-aminobenzamide (13l). 12l 121 mg, 0.35 mmol) was converted to
the corresponding hydroxamic acid according to general procedure C
to give 58 mg (47%) of oﬀ-white solid: 1H NMR (DMSO) δ 11.03 (d,
J = 0.9 Hz, 1H), 9.06 (d, J = 1.2 Hz, 1H), 8.53 (d, J = 8.1 Hz, 1H),
8.48 (d, J = 2.4 Hz, 1H), 7.82 (d, J = 8.7 Hz, 2H), 7.74 (d, J = 1.5 Hz,
1H), 7.60 (d, J = 8.6 Hz, 2H), 7.17−6.91 (m, 3H), 6.70 (ddd, J = 7.6/
2.2/1.2 Hz, 1H), 6.62−6.45 (m, 1H), 5.59 (d, J = 8.1 Hz, 1H), 5.25 (s,
2H); 13C NMR (DMSO) δ 166.8, 166.6, 148.7, 141.0, 139.1, 136.5,
134.6, 128.7, 128.4, 127.8, 118.3, 116.7, 114.8, 113.0, 107.9, 53.9; MS
(TOF ES+) m/z C18H18N5O3 [MH]
+ calcd 352.1, found 352.2; LC/
MS tR = 3.14.
N-(1-(4-(1H-Pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)-
4-aminobenzamide (13m). 12m (46 mg, 0.13 mmol) was converted
to the corresponding hydroxamic acid according to general procedure
C to give 20 mg (43%) of oﬀ-white solid: 1H NMR (DMSO) δ 11.01
(s, 1H), 9.02 (s, 1H), 8.48 (d, J = 2.2 Hz, 1H), 8.31 (d, J = 8.2 Hz,
1H), 7.81 (d, J = 8.7 Hz, 2H), 7.73 (d, J = 1.5 Hz, 1H), 7.66 (d, J = 8.7
Hz, 2H), 7.59 (d, J = 8.6 Hz, 2H), 6.65−6.39 (m, 3H), 5.67 (s, 2H),
5.60 (d, J = 8.2 Hz, 1H); 13C NMR (DMSO) δ 166.9, 166.0, 152.0,
141.0, 139.1, 136.8, 129.3, 128.5, 127.8, 120.2, 118.2, 112.5, 107.9,
53.8; MS (TOF ES−) m/z C18H16N5O3 [M − H]− calcd 350.1, found
350.1; LC/MS tR = 3.19.
Biochemistry. Preparation of Recombinant MAPs. The produc-
tion of recombinant malaria aminopeptidases in Escherichia coli and
puriﬁcation using a two-step puriﬁcation process with a Ni−NTA−
agarose column followed by size exclusion chromatography on a
Superdex 200 16/60 column using an AKTAxpress high-throughput
chromatography system (http://proteinexpress.med.monash.eud.au/
index.htm) was as described.7,9 Biochemical analysis indicated that the
kinetic parameters (kcat, Km, kcat/Km) of material puriﬁed and used in
subsequent crystallization trials were the same as published.7,9
Enzymatic Analysis. The aminopeptidase activity of enzymes was
determined by measuring the release of the ﬂuorogenic leaving group,
NHMec, from the ﬂuorogenic peptide L-leucine-7-amido-4-methyl-
coumarin hydrochloride (H-Leu-NHMec) (Sigma L2145). The assay
protocol devised by Stack et al. was modiﬁed and used.5 The reactions
were carried out in 96-well microtiter plates, with a 200 μL total
volume at 37 °C, using a spectroﬂuorimeter (BMG FLUOstar) with
excitation at 355 nm and emission at 460 nm. PfA-M1 was
preincubated in 100 mM Tris (pH 8.0) at 37 °C and PfA-M17 in
50 mM Tris (pH 8.0) and 2 mM CoCl2 with the inhibitors for 10 min
prior to the addition of substrate. Inhibitor concentrations were
assayed between 0 and 500 μM. The ﬂuorescence signal was
monitored until a ﬁnal steady-state velocity, V, was obtained. The Ki
values were then evaluated using Dixon plots of 1/V versus inhibitor
concentration while the substrate concentration was maintained lower
than that of the Km of the enzyme.
Crystallization and X-ray Data Collection. Crystals of the PfA-M1-
bound complexes were obtained by cocrystallization of each
compound with PfA-M1 in mother liquor containing 1 mM ligand.
For PfA-M17-bound complexes, prior to data collection, crystals were
soaked in mother liquor containing 1 mM ligand and 1 mM ZnSO4.
Data were collected at 100 K using synchrotron radiation at the
Australian Synchrotron using the macrocrystallography MX1 beamline
3BM1 for PfA-M1 and the microcrystallography MX2 beamline 3ID1
for PfA-M17. Diﬀraction images were processed using iMosﬂm,55
XDS,56 pointless,57,58 and SCALA57 from the CCP4 suite.59 A total of
5% of each data set was ﬂagged for calculation of Rfree
60 with neither a
σ nor a low-resolution cutoﬀ applied to the data. A summary of
statistics is provided in Supplementary Table 1 (Supporting
Information). Subsequent crystallographic and structural analysis was
performed using the Phenix suite.61,62 The inhibitor complex was
initially solved and reﬁned against the unbound PfA-M1 and PfA-M17
structures (protein atoms only) as described previously7,9,13,63,64 and
clearly showed unbiased features in the active site for each structure.
The coordinates and structure factors are available from the Protein
Data Bank (PDB accession codes 4R5T, 4R5V, 4R5X, 4R6T, 4R76,
and 4R7M). Raw data and images are available from TARDIS
(https://store.synchrotron.org.au).65,66
Molecular Docking. Molecular docking was carried out by means of
Molegro Virtual Docker (MVD) software ( CLCbio). Ligands were
built and energy minimized by using the PRODRG server.67 Flexible
torsions were automatically detected by MVD and manually checked
for consistency. The obtained three-dimensional structures of PfA-M1
and PfA-M17 were prepared by automatically assigning bond orders
and hybridization and adding explicit hydrogens, charges, and Tripos
atom types. Missing heavy atoms were ﬁxed by modeling them using
Modeler v.9.868 and PyMod.69 A search space of 12 Å radius, centered
on 7, was used for docking. Side chain ﬂexibility and displaceable
waters were set for atoms at 5 Å or less from 7. The hydroxamic acid
and NH of the Boc group of 7 were taken as electrostatic
pharmacophoric groups for template-based dockings. In this way, if
an atom of the ligand matches a group deﬁnition (e.g., positively/
negatively charged), it is rewarded by using a weighted score (w) that
depends on its distance to the group centers by using the following
Gaussian function for each center:
ω= −w d rexp( / )2 02 (1)
where d is the distance (Å) from the position of the atom to the center
in the group, ω is a weight factor for the template group, and r0 is a
distance parameter specifying a characteristic distance for the template
group. ω and r0 were set at 2 and 1.80, respectively. An overall
normalization of the similarity score term, to balance it with other
scoring terms, was then applied for each atom. The grid-based
MolDock score70 with a grid resolution of 0.30 Å was used as the
scoring function for docking. MolDock SE was used as the docking
algorithm. For each ligand, 10 runs were deﬁned. Similar poses
(RMSD < 1.2 Å) were clustered, and the best scoring one was taken as
representative. Other docking parameters were ﬁxed at their default
values. After docking, energy optimization of hydrogen bonds was
performed.
Biology. P. falciparum Culture. An in vitro parasite culture of the
P. falciparum strain 3D7 was maintained in RPMI with 10 mM Hepes
(Life Technologies), 50 μg/mL hypoxanthine (Sigma), and 5 mg/mL
AlbuMAX II (Life Technologies). Human 0+ erythrocytes were
obtained from the Australian Red Cross Blood Service (Agreement
No. 13-04QLD-09). The parasites were maintained at 2−8%
parasitemia at 5% hematocrit and incubated at 37 °C, 5% CO2, 5%
O2, 90% N2, and 95% humidity.
P. falciparum Growth Inhibition Assay. A well-established P.
falciparum imaging assay was used to assess parasite growth
inhibition.47 In brief, sorbitol (5%, w/v) synchronization was
performed twice, approximately 8 h apart, on each synchronization
day for two consecutive ring cycles, i.e., on days 1 and 3 of assay
preparation. On day 2 the culture was split to approximately 2%
trophozoite parasitemia. On day 4 the culture was split to 1−1.5%
trophozoite parasitemia, which yielded approximately 8% ring
parasitemia after 48 h on day 5, the day of the assay setup.
Compound stocks (10 mM in 100% DMSO) were diluted 1:25 in
sterile water less than 24 h prior to use. An additional 1:10 dilution
was performed, resulting in a 1:250 overall compound dilution and a
ﬁnal DMSO concentration of 0.4%. For dose response curves a three-
step logarithmic serial dilution in 4% DMSO was prepared at 40 μM
top concentration for test compounds and 2 μM for the positive
control, artemisinin. A 5 μL volume of the diluted test compound or
control solutions (20 μM artemisinin as the positive control and 4%
DMSO as the negative control) were added to 384-well CellCarrier
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imaging plates (PerkinElmer) for a ﬁnal 1:10 dilution in parasite
culture. The resulting ﬁnal DMSO concentration for all sample
dilutions and controls was 0.4%.
The parasite culture was added to a ﬁnal concentration of 2%
parasitemia and 0.3% hematocrit. The plates were incubated for 72 h
at 37 °C, 5% CO2, and 95% humidity. On day 8 the permeabilization
and nuclear staining buﬀer was prepared in PBS containing10 μg/mL
saponin, 0.01% Triton X, and 5 mM EDTA (all Sigma) and 0.5 μg/mL
4′,6-diamidino-2-phenylindole (DAPI; Life Technologies).47
The plates were incubated at rt overnight before confocal imaging
on an Opera confocal imager (PerkinElmer) at 405 nm excitation with
a 20× water objective. Automated primary image analysis was
performed concurrent with the imaging process utilizing an Acapella
software (PerkinElmer) script to determine the number of parasites on
the basis of the object size and ﬂuorescence intensity.47 Determination
of the percentage of growth compared to the controls (2 μM
artemisinin as the positive control and 0.4% DMSO as the negative
control) was performed in Microsoft Excel 2010. Statistical analysis
including IC50 determination and graphical output was performed in
GraphPad Prism 5 using nonlinear regression variable-slope curve
ﬁtting.
HEK293 Viability Assay. To assess the cytotoxicity of the
compounds in dose response, a resazurin-based assay was utilized to
test for cell viability. In brief, HEK293 cells were grown in DMEM
medium (Life Technologies) containing 10% fetal calf serum (FCS;
Gibco). The cells were trypsinized, counted, and seeded at 2000 cells
per well in 45 μL of medium in TC-treated 384-well plates (Falcon)
and left to adhere overnight at 37 °C, 5% CO2, and 95% humidity.
Test compounds were prepared as described above to give a top
ﬁnal test concentration of 40 μM 0.4% DMSO. The plates were
incubated for 72 h at 37 °C, 5% CO2, and 95% humidity, and then the
medium was removed and replaced by 35 μL of 44 μM resazurin in
DMEM without FCS. The plates were incubated for another 4−6 h at
37 °C, 5% CO2, and 95% humidity before being read on an EnVision
plate reader (PerkinElmer) using ﬂuorescence excitation/emission
settings of 530 nm/595 nm. Determination of the percentage of
growth compared to the controls (40 μM puromycin as the positive
control and 0.4% DMSO as the negative control) was performed in
Microsoft Excel 2010. Statistical analysis including IC50 determination
and graphical output was performed in GraphPad Prism 5 using
nonlinear regression variable-slope curve ﬁtting.
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